KR20100091393A - Food for improving cholesterol and lipid metabolism - Google Patents
Food for improving cholesterol and lipid metabolism Download PDFInfo
- Publication number
- KR20100091393A KR20100091393A KR1020090010566A KR20090010566A KR20100091393A KR 20100091393 A KR20100091393 A KR 20100091393A KR 1020090010566 A KR1020090010566 A KR 1020090010566A KR 20090010566 A KR20090010566 A KR 20090010566A KR 20100091393 A KR20100091393 A KR 20100091393A
- Authority
- KR
- South Korea
- Prior art keywords
- cholesterol
- bacillus subtilis
- mixture
- lipid metabolism
- soybean meal
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 333
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 150
- 230000037356 lipid metabolism Effects 0.000 title claims abstract description 33
- 235000013305 food Nutrition 0.000 title claims abstract description 32
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 57
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 53
- 235000019764 Soybean Meal Nutrition 0.000 claims abstract description 46
- 239000004455 soybean meal Substances 0.000 claims abstract description 46
- 240000004922 Vigna radiata Species 0.000 claims abstract description 43
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 42
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 17
- 239000012153 distilled water Substances 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims description 54
- 230000004151 fermentation Effects 0.000 claims description 54
- 235000010469 Glycine max Nutrition 0.000 claims description 26
- 244000068988 Glycine max Species 0.000 claims description 17
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000010411 cooking Methods 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 238000012792 lyophilization process Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 239000012531 culture fluid Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 68
- 150000002632 lipids Chemical class 0.000 description 42
- 239000000243 solution Substances 0.000 description 35
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 32
- 210000004185 liver Anatomy 0.000 description 31
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 30
- 239000000047 product Substances 0.000 description 28
- 235000005911 diet Nutrition 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 239000003925 fat Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 20
- 230000037213 diet Effects 0.000 description 18
- 244000013123 dwarf bean Species 0.000 description 17
- 235000009200 high fat diet Nutrition 0.000 description 17
- 108010073771 Soybean Proteins Proteins 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 15
- 244000046052 Phaseolus vulgaris Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 235000021331 green beans Nutrition 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 108010010234 HDL Lipoproteins Proteins 0.000 description 13
- 238000008214 LDL Cholesterol Methods 0.000 description 13
- 210000005228 liver tissue Anatomy 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 201000010063 epididymitis Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 235000019710 soybean protein Nutrition 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 210000000579 abdominal fat Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000000378 dietary effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 7
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 7
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 7
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 7
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 7
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229940001941 soy protein Drugs 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 239000011345 viscous material Substances 0.000 description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 5
- 101710117029 Peroxisome proliferator-activated receptor delta Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000021438 curry Nutrition 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000010200 folin Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 108010010256 Dietary Proteins Proteins 0.000 description 4
- 102000015781 Dietary Proteins Human genes 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 4
- 108090000637 alpha-Amylases Proteins 0.000 description 4
- 229940024171 alpha-amylase Drugs 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 108010083364 chungkookjang Proteins 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 235000021245 dietary protein Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229920002643 polyglutamic acid Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000003109 clavicle Anatomy 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 2
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- 102000018619 Apolipoproteins A Human genes 0.000 description 2
- 108010027004 Apolipoproteins A Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 244000227473 Corchorus olitorius Species 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 235000013367 dietary fats Nutrition 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 235000001916 dieting Nutrition 0.000 description 2
- 230000037228 dieting effect Effects 0.000 description 2
- -1 edible mushrooms Natural products 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000013379 physicochemical characterization Methods 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108091006091 regulatory enzymes Proteins 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000010206 Corchorus olitorius Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100168115 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-6 gene Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 241000001493 Sarcodon aspratus Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/001—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from waste materials, e.g. kitchen waste
- A23J1/005—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from waste materials, e.g. kitchen waste from vegetable waste materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/006—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from vegetable materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
- A23J3/16—Vegetable proteins from soybean
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/20—Freezing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Agronomy & Crop Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 콜레스테롤 및 지질대사 개선을 위한 식품에 관한 것으로서, 탈지대두박 발효물 및 녹두 발효물의 혼합물이 갖는 콜레스테롤 및 지질대사 개선을 위한 식품으로서의 용도에 관한 것이다. The present invention relates to a food for improving cholesterol and lipid metabolism, and relates to a food for improving cholesterol and lipid metabolism of a mixture of skim soybean meal fermentation and green beans fermentation.
고도의 산업화와 경제적 수준의 향상으로 식생활 패턴이 서구화되면서 최근 한국인의 사망원인을 살펴보면, 뇌혈관계 질환, 악성 종양, 고혈압 및 심장 질환 등이 높은 비중을 차지하고 있으며, 소아 성인병 또한 증가추세에 있어 국민 보건에 심각한 문제점으로 지적되고 있다. 특히 동물성 식품과 정제된 식품의 섭취량 증가는 지방간, 동맥경화, 심혈관계질환, 고지혈증, 고혈압 등의 합병증을 수반한다. 이 중 고지혈증은 혈장 내 콜레스테롤이나 중성지방이 비정상적으로 증가된 상태이고, 그 중 고콜레스테롤혈증은 죽상동맥경화증과 고중성지방혈증을 유발하는 것으로 알려져 있다. 이러한 추세에 따라 고지혈증 개선을 위한 콜레스테롤 합성저 해제가 다방면으로 연구되고 있다.As the pattern of eating habits has been westernized due to the high industrialization and the economic level, the cause of death of Koreans is high. Cerebrovascular disease, malignant tumors, hypertension and heart disease account for a high proportion. Has been pointed out as a serious issue. In particular, increased intake of animal and purified foods is accompanied by complications such as fatty liver, arteriosclerosis, cardiovascular diseases, hyperlipidemia, hypertension. Among these, hyperlipidemia is a condition in which cholesterol or triglycerides are abnormally increased, and hypercholesterolemia is known to cause atherosclerosis and hypertriglyceridemia. According to this trend, cholesterol synthesis inhibitors to improve hyperlipidemia have been studied in various fields.
콜레스테롤 생합성 과정 중 3-하이드록시-3-메틸글루타릴 코엔자임 A(3-hydroxy-3-methylglutaryl coenzyme A, 이하 HMG-CoA으로 약칭.)로부터 메발로네이트(mevalonate)로 전환시키는 효소인 HMG-CoA 리덕타아제는 콜레스테롤 합성속도의 주요 조절 효소이며, 간 내에 HMG-CoA 리덕타아제 활성의 저하는 간의 LDL-수용체(receptor)의 활성을 증가시켜 혈중 콜레스테롤 농도를 감소시킨다고 보고되고 있다(Sitory, C. R. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharm. Res. 1990, 22, 555-562; Qureshi, A. A.; Abuimeileh, N.; Din, Z. Z.; Elson, C. E.; Burger, W. C. Inhibition of cholesterol and fatty acid biosynthesis in liver enzymes and chicken hepatocytes by polar fractions of garlic. Lipids. 1983, 18, 343-348; Qureshi, A. A., Burger W. C. Peterson D. M., Elson, C. E.: Suppression of cholesterogenesis by plant constituents: review of wisconsin contributions to NC-167. Lipids. 1985, 20, 817-824. 기재 참조). HMG-, an enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A (hereinafter referred to as HMG-CoA) into mevalonate during cholesterol biosynthesis. CoA reductase is a major regulator of cholesterol synthesis rate, and it has been reported that a decrease in HMG-CoA reductase activity in the liver decreases blood cholesterol levels by increasing the activity of LDL-receptors in the liver (Sitory, . CR Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors Pharm Res 1990, 22, 555-562;.. Qureshi, AA; Abuimeileh, N .; Din, ZZ; Elson, CE; Burger, WC Inhibition of cholesterol and fatty acid biosynthesis in liver enzymes and chicken hepatocytes by polar fractions of garlic.Lipids . 1983 , 18, 343-348; Qureshi, AA, Burger WC Peterson DM, Elson, CE: Suppression of cholesterogenesis by plant constituents: review of wisconsin contributions to NC-167. Lipids. 1985 , 20, 817-824. See description).
이러한 고지혈증 및 고콜레스테롤혈증의 치료제로써 최근 가장 많이 사용되는 것은 로바스타틴(lovastatin), 심바스타틴(simvastatin), 프라바스타틴(pravastatin), 플루바스타틴(fluvastatin), 아토바스타틴(atorvastatin) 및 세바스타틴(cervastatin) 등의 스타틴류(statin)의 물질이다. 스타틴류의 물질은 생체 내에서 콜레스테롤의 합성을 저해하여 결과적으로 콜레스테롤 양을 현저히 낮출 수 있지만, 심각한 근육통 등의 부작용들을 수반한다. 그러므로 부작용 없이 콜레 스테롤 합성을 저해하는 생리활성물질을 찾아내려는 연구가 활발하게 진행되고 있다. Most recently used as a treatment for such hyperlipidemia and hypercholesterolemia is lovastatin, simvastatin, simvastatin, pravastatin, fluvastatin, atorvastatin and cevastatin It is a substance of statins. Statins can inhibit the synthesis of cholesterol in vivo and consequently lower the amount of cholesterol, but also involve side effects such as severe muscle pain. Therefore, studies are actively underway to find bioactive substances that inhibit cholesterol synthesis without side effects.
한편, 단백질이 혈중 콜레스테롤 농도와 동맥경화에 영향을 미친다는 것이 보고 되었으며(Iwami, K.; Sakakibara, K.; Ibuki, F. Involvement of post-digestrion hydrophobic peptides in plasma cholesterol lowering effect of dietary plant proteins. Agric. Biol. Chem. 1986, 50, 1217; Sugano, M.; Goto, S.; Yamada, Y.; Toshida, K, M.; Hashimoto, Y.; Matsuno, T.; Kimoto, M. Cholesterol-lowering activity of various undigested fraction of soybean protein in rats. J. Nutr. 1990, 120, 977-985; Iritani, N.; Hosomi, H.; Fukuda, H.; Tada, K.; Ikeda, H. Soybean protein suppresses hepatic lipogenic enzyme gene expression in wister fatty rats. J. Nutr. 1996, 126, 380-388.; Moi, M. A. E.; Smet, R. C.; Terpstra, A. H. M.; West, C. E. Effect of dietary protein and cholesterol on cholesterol concentration and lipoprotein pattern in the serum of chickens. J. Nut. 1982, 112, 1029-1037. 참조), 특히 대두 단백질이 동물성 단백질인 카제인에 비해 혈중 콜레스테롤 농도를 저하하는 효과가 현저하다는 연구들이 많이 보고되었다(Huff, M. W.; Carrol, K. K. Effects of dietary proteins and amino acid mixtures on plasma cholesterol levels in rabbits. J. Nutr. 1980, 110, 1676-1685.; Park, M. S.; Liepa, G. U. Effects of dietary protein and amino acids on the metabolism of cholesterol-carring lipoproteins in rats. J. Nutr. 1982, 112, 1892-1898.; Sautier, C.; Doucet, C.; Flament, C.; Lemonnier, D. Effect of soy protein and saponins on serum, tissue and feces steroids in rats. Atherosclerosis. 1979, 34, 233-241.; Sirtori, C. R.; Agra, E.; Conti, F.; Gatti, E.; Mantero, O.; Tremili, E.; Sirtori, M.; Fraterrigo, L.; Tavazzi, L.; Kritxhevsky, D. Clinical experience with the soybean protein diet in the treatment of hypercholesterolemia. Am. J. Clin. Nutr. 1979, 32, 1645-1658. 참조). Meanwhile, it has been reported that proteins affect blood cholesterol levels and atherosclerosis (Iwami, K .; Sakakibara, K .; Ibuki, F. Involvement of post-digestrion hydrophobic peptides in plasma cholesterol lowering effect of dietary plant proteins. Agric. Biol. Chem . 1986 , 50, 1217; Sugano, M .; Goto, S .; Yamada, Y .; Toshida, K, M .; Hashimoto, Y .; Matsuno, T .; Kimoto, M. Cholesterol- lowering activity of various undigested fraction of soybean protein in rats.J. Nutr. 1990 , 120, 977-985; Iritani, N .; Hosomi, H .; Fukuda, H .; Tada, K .; Ikeda, H. Soybean protein suppresses hepatic lipogenic enzyme gene expression in wister fatty rats.J. Nutr. 1996 , 126, 380-388 .; Moi, MAE; Smet, RC; Terpstra, AHM; West, CE Effect of dietary protein and cholesterol on cholesterol concentration and lipoprotein pattern in the serum of chickens.J. Nut. 1982, 112, 1029-1037.), especially the concentration of blood cholesterol in soybean protein compared to casein, an animal protein. A number of studies have reported that the effect of lowering the level of blood sugar is significant (Huff, MW; Carrol, KK Effects of dietary proteins and amino acid mixtures on plasma cholesterol levels in rabbits. J. Nutr. 1980 , 110, 1676-1685 .; Park, MS; Liepa, GU Effects of dietary protein and amino acids on the metabolism of cholesterol-carring lipoproteins in rats. J. Nutr. 1982 , 112, 1892-1898 .; Sautier, C .; Doucet, C .; Flament, C .; Lemonnier, D. Effect of soy protein and saponins on serum, tissue and feces steroids in rats. Atherosclerosis. 1979 , 34, 233-241 .; Sirtori, CR; Agra, E .; Conti, F .; Gatti, E .; Mantero, O .; Tremili, E .; Sirtori, M .; Fraterrigo, L .; Tavazzi, L .; Kritxhevsky, D. Clinical experience with the soybean protein diet in the treatment of hypercholesterolemia. Am. J. Clin. Nutr. 1979 , 32, 1645-1658. Reference).
대두 단백질의 혈중 콜레스테롤 저하효과에 대한 기전으로 첫째, 대두 단백질의 섭취가 간에서 콜레스테롤 합성 율속 효소인 HMG-CoA 리덕타아제의 활성에 영향을 준다는 보고(Forsythe, W. A. Comparison of dietary casein or soy protein effects on plasma lipids and hormone concentrations in the gerbil. J. Nutr. 1986, 116, 1165-1171. 참조)와, 특정 아미노산의 비율이 혈중 콜레스테롤 농도를 감소시킨다는 보고(Milner, J. A.; Hassan, A. S. Species specificity of arginine deficiency-induced hepatic steatosis. J. Nutr. 1981, 111, 1067-1073.; Forsythe, W. A.; Miller, E. R.; Hill, G. M.; Romsos, D. R.; Simpson, R. C. Effects of dietary protein and fat sources on plasma cholesterol parameters, LCAT activity and amino acid levels on tissue lipid content of growing pogs. J. Nutr. 1980, 110, 2467-2479.참조)들이 있다. 둘째, 대두 단백질의 섭취가 분변으로의 담즙산 배설을 증가시켜 간의 콜레스테롤은 더 많은 담즙산을 생성하기 위하여 사용되며 혈액으로부터 apolipoprotein B/E 수용체를 통해 콜레스테롤을 제공받아 혈장 콜레스테롤 농도를 저하시켜 체내 콜레스테롤 pool을 감 소시킨다고 보고되었다(Iwami, K.; Sakakibara, K.; Ibuki, F. Involvement of post-digestrion hydrophobic peptides in plasma cholesterol lowering effect of dietary plant proteins. Agric. Biol. Chem. 1986, 50, 1217. ; Sugano, M.; Goto, S.; Yamada, Y.; Toshida, K, M.; Hashimoto, Y.; Matsuno, T.; Kimoto, M. Cholesterol-lowering activity of various undigested fraction of soybean protein in rats. J. Nutr. 1990, 120, 977-985. 참조). 셋째, 내분비계에 영향을 미쳐 혈중 글루카곤/인슐린 비의 감소(Potter, S. M. Overview of proposed mechanisims for the hypocholesterolemic effect of soy. J. Nutr. 1995, 125, 606-611 . 참조)와 티록신(thyroxine) 농도를 증가시켜 혈중 중성지방과 콜레스테롤 농도를 감소시킨다는 보고(Forsythe, W. A. Soy protein, thyroid regulation and cholesterol metabolism. J. Nutr. 1995, 125, 619-623. 참조)들이 있다. As a mechanism for lowering cholesterol in the blood, soy protein has been shown to affect the activity of HMG-CoA reductase, a cholesterol synthesis rate enzyme in the liver (Forsythe, WA Comparison of dietary casein or soy protein effects). on plasma lipids and hormone concentrations in the gerbil.J. Nutr. 1986 , 116, 1165-1171.) and reports that certain amino acid ratios reduce blood cholesterol levels (Milner, JA; Hassan, AS Species specificity of arginine). deficiency-induced hepatic steatosis.J. Nutr . 1981 , 111, 1067-1073 .; Forsythe, WA; Miller, ER; Hill, GM; Romsos, DR; Simpson, RC Effects of dietary protein and fat sources on plasma cholesterol parameters, LCAT activity and amino acid levels on tissue lipid content of growing pogs. J. Nutr. 1980 , 110, 2467-2479. Second, ingestion of soy protein increases the excretion of bile acids into the feces, and liver cholesterol is used to produce more bile acids, and cholesterol is supplied from the blood through the apolipoprotein B / E receptor to lower plasma cholesterol levels, thereby reducing the cholesterol pool in the body. (Iwami, K .; Sakakibara, K .; Ibuki, F. Involvement of post-digestrion hydrophobic peptides in plasma cholesterol lowering effect of dietary plant proteins.Agric . Biol. Chem . 1986 , 50, 1217 .; Sugano, M .; Goto, S .; Yamada, Y .; Toshida, K, M .; Hashimoto, Y .; Matsuno, T .; Kimoto, M. Cholesterol-lowering activity of various undigested fraction of soybean protein in rats. J. Nutr. 1990 , 120, 977-985.). Third, decrease in blood glucagon / insulin ratio by affecting the endocrine system (see Potter, SM Overview of proposed mechanisims for the hypocholesterolemic effect of soy. J. Nutr. 1995 , 125, 606-611) and thyroxine concentrations There are reports of increasing triglyceride and cholesterol levels in the blood (see Forsythe, WA Soy protein, thyroid regulation and cholesterol metabolism. J. Nutr. 1995 , 125, 619-623.).
또한 대두의 발효과정 중 쏘이 펩타이드류 (soy peptides), 글루불린류(glubulins), 이소플라본류(isoflavones), 사포닌 등의 물질이 생산되어(Choi, Y. B.; Sohn, H. S. Isoflavone content in Korean fermented and unfermented soybean foods. Korean J. Food Sci. Technol. 1998, 30, 745-750. 참조) 혈전용해능(Hso, S.; Lee, S. K.; Joo, H. K. Isolation and identification of fibrinolytic bacteria from Korean traditional chugkookjang. J. Korean Soc. Agric. Chem. Biotechnol. 1998, 41, 119-124. 참조), 항암(Kwon, E. Y. Standardization of Chungkookjang preparation and its cancer preventive effect. M. S. Thesis. Pusan National University, Pusan. 2000. 참조), 항산화 및 항동맥경화 효과(Yang, J. L. Antiatherogenic effect of chonkukjang. Dissertation of Ph. D., Pusan National University, Pusan. 2000.), 그리고 혈당조절 및 혈중 중성지질 및 콜레스테롤 감소로 인한 지질대사를 개선하는 기능(Kang, M. J. Antibiabetic effect of soy pinito and Chongkukjang : Animal studies and clinical trials. Dissertation of Ph. D., Inje University, Gimhae. 2004.) 등이 보고되었다. 특히 대두의 고초균 발효과정 중에 생성되는 점질물은 감마-폴리글루탐산(gamma-poly-glutamic acid, γ-PGA)과 프락토오즈 중합체인 레반으로 구성되며, γ-PGA는 칼슘이 인과 결합하여 불용성 염을 형성하는 것을 방지하여 칼슘 용해도를 증가시키며, 레반은 혈중지질 감소효과를 나타내었다. In addition, soy peptides, glubulins, isoflavones and saponins are produced during fermentation of soybeans (Choi, YB; Sohn, HS Isoflavone content in Korean fermented and unfermented). .... soybean foods Korean J. Food Sci Technol 1998, 30, 745-750 see) fibrinolytic function (Hso, S .; Lee, SK ;. Joo, HK Isolation and identification of fibrinolytic bacteria from Korean traditional chugkookjang J. Korean Soc.Agric.Chem.Biotechnol . 1998 , 41, 119-124.), Anti-cancer (see Kwon, EY Standardization of Chungkookjang preparation and its cancer preventive effect.MS Thesis.Pusan National University, Pusan. 2000. ), antioxidant And anti-arterial effect (Yang, JL Antiatherogenic effect of chonkukjang. Dissertation of Ph. D., Pusan National University, Pusan. 2000. ), and the ability to improve lipid metabolism due to glycemic control and decrease of blood triglycerides and cholesterol ( Kang, MJ Antibiabetic effect of soy pinito and C hongkukjang: Animal studies and clinical trials.Dissertation of Ph. D., Inje University, Gimhae. 2004 . In particular, the viscous material produced during the fermentation process of soybean bacterium is composed of gamma-poly-glutamic acid (γ-PGA) and levan, a fructose polymer, and γ-PGA combines calcium with phosphorus to form insoluble salts. It prevents the formation and increases calcium solubility, and Levan showed blood lipid reduction effect.
대두는 우리나라 국민이 가장 많이 섭취하는 두류로서 육류의 대체 영양공급원으로 다양하게 이용되고 있는 식품이며, 발효제품, 발아제품, 기타 가공식품 등의 식품으로서 이용도가 높을 뿐 아니라 공업용, 의약용, 화장품, 비누 등의 원료로도 널리 이용되고 있다. 새로운 단백질 식품의 소재로써 상업적으로 생산되고 있는 탈지대두박(defatted soybean grit), 농축대두단백(soybean protein concentrate), 분리대두단백(soybean protein isolate) 및 조직대두단백(textured soybean protein) 등의 이용도 증가하고 있다. Soybean is the most commonly consumed soybean in Korea, and it is widely used as an alternative source of nutrition for meat. It is also widely used as food such as fermented products, germinated products, and processed foods. It is also widely used as a raw material such as soap. Increased availability of commercially produced defatted soybean grit, soybean protein concentrate, soybean protein isolate and textured soybean protein as new protein foods Doing.
특히 탈지대두박은 대두유 제조로 생산되는 부산물로, 외피를 제거한 대두로부터 만들어져 상대적으로 낮은 섬유소를 가지고, 높은 단백질 함량을 가지며, 지질 함량이 1% 이하이다. In particular, defatted soybean meal is a by-product produced by soybean oil production, which is made from soybean with the skin removed, has relatively low fiber, has a high protein content, and has a lipid content of 1% or less.
본 발명의 일 구현예에서는 탈지대두박을 B. subtilis 균주로 고체 발효시킨 탈지대두박 발효물과 HMG-CoA 리덕타아제 저해활성이 우수한 천연물의 발효물의 혼합물에 대하여 in vitro 및 in vivo 상에서 콜레스테롤 및 지질대사 개선능을 비교 검색하여, 이들 발효물의 콜레스테롤 및 지질대사 개선능을 가지는 새로운 식품 소재로서의 용도를 제공하고자 한다. In one embodiment of the present invention, cholesterol and lipid metabolism in vitro and in vivo for a mixture of fermented skim soybean meal fermented with B. subtilis strains and natural fermentation products having excellent HMG-CoA reductase inhibitory activity. The comparative search for improvement ability is intended to provide a use as a new food material having the ability to improve cholesterol and lipid metabolism of these fermentations.
본 발명의 일 구현예에서는 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 및 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물의 혼합물을 포함하는 콜레스테롤 및 지질대사 개선을 도모하는 식품을 제공한다. In one embodiment of the present invention Bacillus subtilis ( Bacillus) subtilis) fermented soybean meal, and the cleaning of Bacillus subtilis by subtilis (Bacillus Subtilis ) provides a food for improving cholesterol and lipid metabolism, including a mixture of fermentation products.
바람직한 본 발명의 일 구현예에 의한 식품에 있어서, 혼합물은 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물을 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 100중량부에 대해 0.1 내지 10중량부로 포함하는 것일 수 있다.In a preferred food according to one embodiment of the present invention, the mixture is Bacillus subtilis of mung beans ( Bacillus subtilis) of defatted soybean meal fermented by the Bacillus subtilis (Bacillus subtilis ) may be included in an amount of 0.1 to 10 parts by weight based on 100 parts by weight of the fermented product.
본 발명의 일 구현예에 의한 식품에 있어서, 혼합물은, 증자한 탈지대두박과 녹두 분말의 혼합물을, 바실러스 서브틸리스( Bacillus subtilis )로 고체 발효시켜 얻어지는 것일 수 있으며, 구체적으로는 탈지대두박 100중량부에 녹두 분말 0.1 내지 10중량부를 혼합하고 증류수를 가하여 멸균 및 증자하여, 멸균된 녹두 첨가 탈지대두박 용액을 제조하는 공정; 멸균된 대두분말 용액 중에서 바실러스 서브틸리 스( Bacillus subtilis )를 40~42℃에서 46~48시간 동안 배양하여 배양액을 제조하는 공정; 및 멸균된 녹두 첨가 탈지대두박 용액에 배양액을 접종한 후 40~42℃에서 24~26 시간 발효시키는 공정을 수행하여 얻어지는 것일 수 있다. In the foodstuff according to one embodiment of the present invention, the mixture is a mixture of steamed skim soybean meal and mung bean powder, Bacillus subtilis ( Bacillus subtilis ), which may be obtained by solid fermentation, specifically, 0.1 to 10 parts by weight of mung bean powder to 100 parts by weight of defatted soybean meal, and sterilization and steaming by adding distilled water to prepare a sterilized mung bean-added defatted soybean meal solution; In a sterile soy flour solution Bacillus subtilis (Bacillus subtilis ) to incubate for 46 to 48 hours at 40 ~ 42 ℃ to prepare a culture solution; And after inoculating the culture solution in sterilized mung bean added skim soybean meal solution may be obtained by performing a step of fermentation for 24 to 26 hours at 40 ~ 42 ℃.
본 발명의 일 구현예에 의한 식품에 있어서, 혼합물은 동결건조물일 수 있다. In the foodstuff according to one embodiment of the present invention, the mixture may be a lyophilisate.
본 발명의 일 구현예에 의한 식품에 있어서, 혼합물은 발효 공정 이후에 동결건조 공정을 더 수행하여 얻어질 수 있다. In the foodstuff according to one embodiment of the present invention, the mixture may be obtained by further performing a lyophilization process after the fermentation process.
본 발명의 일 구현예에 의하면 탈지대두(DSG)에 녹두를 첨가하여 바실러스 서브틸리스균( Bacillus sbutlis )을 이용한 고체발효를 행하여 얻어지는 발효물은 in vitro 상에서 콜레스테롤 개선능을 검색한 결과 콜레스테롤 흡착능과 HMG-CoA 리덕타아제 저해활성 및 HepG2 세포에서의 콜레스테롤 조절능이 우수함을 확인하였으며, 또한 HepG2 세포에서 apolipoprotein AI, AII 활성 증가 및 apolipoprotein CIII의 활성 저해 효과가 우수함을 확인하였다.According to an embodiment of the present invention by adding mung bean to degreasing soybean (DSG) Bacillus subtilis bacteria ( Bacillus fermented product obtained subjected to a solid-state fermentation using sbutlis) was confirmed excellent cholesterol control in the resulting cholesterol adsorbability searching cholesterol improved performance and HMG-CoA reductase inhibitory activity and HepG2 cells ability on the in vitro, also in the HepG2 cells It was confirmed that apolipoprotein AI, AII activity increase and apolipoprotein CIII activity inhibitory effect is excellent.
또한 티로신 및 점질물 함량이 20 배 이상 증가되며 프로테아제 활성과 α-아밀라아제 활성이 높다. In addition, the content of tyrosine and slime is more than 20 times higher and the protease activity and the α-amylase activity are high.
또한 In vivo 상에서의 체내 콜레스테롤 함량변화를 측정한 결과, 콜레스테롤 및 지질 개선효과를 보였고 특히 혈장 및 간 내의 콜레스테롤과 TG 함량이 감소되었고, 변 내 콜레스테롤 및 TG 함량의 배출이 증가되었다. 또한 간 내의 HMG-CoA 리덕타아제 활성을 저해하여 콜레스테롤 및 지질대사가 조절되었다. In addition, the changes in cholesterol content in the body were measured to improve cholesterol and lipids, and in particular, plasma and liver cholesterol and TG contents were decreased, and fecal cholesterol and TG contents were increased. In addition, cholesterol and lipid metabolism were regulated by inhibiting HMG-CoA reductase activity in the liver.
따라서, 본 발명의 일 구현예들에 의한 탈지대두박 발효물과 녹두 발효물의 혼합물은 콜레스테롤과 지질대사 개선효과를 가지고 있으며, 이로써 콜레스테롤 및 지질대사 개선능에 관련된 기능성 식품 천연소재로서 유용성을 기대할 수 있다.Therefore, the mixture of skim soybean meal fermentation and mung bean fermentation according to an embodiment of the present invention has an effect of improving cholesterol and lipid metabolism, thereby can be expected to be useful as a functional food natural material related to cholesterol and lipid metabolism improving ability.
이와 같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명의 일 구현예에서는 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 및 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물의 혼합물을 포함하는 콜레스테롤 및 지질대사 개선을 도모하는 식품을 제공한다. 다시 말해, 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 및 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물의 혼합물을 이용한 콜레스테롤 및 지질대사 개선을 도모하는 식품으로서의 용도에 관한 것이다. In one embodiment of the present invention Bacillus subtilis ( Bacillus) subtilis) fermented soybean meal, and the cleaning of Bacillus subtilis by subtilis (Bacillus Subtilis ) provides a food for improving cholesterol and lipid metabolism, including a mixture of fermentation products. In other words, the mung bean of Bacillus subtilis (Bacillus subtilis) fermented soybean meal, and the cleaning of Bacillus subtilis by subtilis (Bacillus subtilis ) and the use as a food to improve cholesterol and lipid metabolism using a mixture of fermented products.
두 발효물을 혼합함에 따른 콜레스테롤 및 지질대사 개선의 상승적인 효과에 있어 최적하기로는, 혼합물은 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물을 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 100중량부에 대해 0.1 내지 10중량부로 포함하는 것이다. Best decided in cholesterol and synergistic effect of improving lipid metabolism resulting from the mixture of the two fermented product is the mixture of green beans Bacillus subtilis (Bacillus subtilis) of defatted soybean meal fermented by the Bacillus subtilis (Bacillus subtilis ) 0.1 to 10 parts by weight based on 100 parts by weight of the fermentation.
탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물에 대하여 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물의 함량이 과 다하면, 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 단독으로 발현되는 콜레스테롤 및 지질대사 개선 효과를 오히려 저감시켜 첨가에 따른 효과를 기대하기 어려울 수 있다. 바람직하기로는 혼합물은 녹두의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물을 탈지대두박의 바실러스 서브틸리스( Bacillus subtilis )에 의한 발효물 100중량부에 대해 0.1 내지 5중량부로 포함하는 것일 수 있다.Defatted soybean meal of Bacillus subtilis (Bacillus of Bacillus with respect to the green beans fermented by subtilis) subtilis (Bacillus subtilis) fermentation of skimmed soybean meal and the water content reaches its end of Bacillus subtilis by subtilis (Bacillus subtilis ) can be difficult to expect the effect of addition to reduce the effect of improving cholesterol and lipid metabolism expressed by the fermentation alone. Preferably the mixture of mung Bacillus subtilis (Bacillus subtilis) of defatted soybean meal fermented by the Bacillus subtilis (Bacillus subtilis ) may be included in an amount of 0.1 to 5 parts by weight based on 100 parts by weight of the fermented product.
이러한 두 발효물의 혼합물은 다양한 방법으로 얻어질 수 있으나, 탈지대두박 및 녹두를 각각 발효하여 혼합하는 경우보다 증자한 탈지대두박과 녹두 분말의 혼합물을, 바실러스 서브틸리스( Bacillus subtilis )로 고체 발효시키는 방법이 발효 중에 효소 생성이나 점질물 함량 등의 증가에 영향을 미치므로 발효적성이나 콜레스테롤 및 지질대사 개선 효과적 측면에서 좋기로는 증자한 탈지대두박과 녹두 분말의 혼합물을, 바실러스 서브틸리스( Bacillus subtilis )로 고체 발효시키는 방법을 들 수 있다. Mixtures of these two fermentations can be obtained in a variety of ways, but rather than mixing and fermenting skim soybean meal and green beans, respectively. The mixture of the defatted soybean and mung bean powder increase, Bacillus subtilis (Bacillus solid fermentation with subtilis ) affects the production of enzymes and the increase in the content of viscous substances during fermentation. Tillis ( Bacillus) subtilis ) and a method of solid fermentation.
좀더 구체적으로는, 먼저 탈지대두박 100중량부에 녹두 분말 0.1 내지 10중량부를 혼합하고 증류수를 가하여 멸균 및 증자하여, 멸균된 녹두 첨가 탈지대두박 용액을 제조한다. More specifically, first, 0.1 to 10 parts by weight of mung bean powder is mixed with 100 parts by weight of skim soybean meal, and sterilized and cooked by adding distilled water to prepare a sterilized mung bean-added skim soybean meal solution.
이때 증류수의 첨가량은 탈지대두박 100중량부에 대해 0.1 내지 10중량부일 수 있다. In this case, the amount of distilled water may be 0.1 to 10 parts by weight based on 100 parts by weight of degreased soybean meal.
멸균 및 증자는 고압멸균기를 이용하여 수행할 수 있으며, 120~121℃에서 15~16분 동안 증자하면 멸균된 탈지대두박 및 녹두 분말의 혼합 용액(멸균된 녹두 첨가 탈지대두박 용액)을 얻을 수 있다. Sterilization and cooking can be carried out using autoclave, At 120 ~ 121 ℃ After 15-16 minutes of cooking, a mixed solution of sterile defatted soybean meal and mung bean powder (sterile mung bean-added defatted soybean meal solution) can be obtained.
멸균된 녹두 첨가 탈지대두박 용액은 발효 공정으로의 이행을 위해 50 내지 60℃로 냉각하여 둔다.The sterilized mung bean-added defatted soybean meal solution is left to cool to 50-60 ° C. for transition to the fermentation process.
이와는 별도로 발효를 수행하기 위한 균주 배양의 공정을 수행하는바, 구체적으로는 멸균된 대두분말 용액 중에서 바실러스 서브틸리스( Bacillus subtilis )를 40~42℃에서 46~48시간 동안 배양하여 배양액을 제조할 수 있다. Apart from this, a process of strain culture for carrying out fermentation is carried out, specifically, Bacillus subtilis ( Bacillus) in a sterile soybean powder solution. subtilis ) may be cultured at 40 to 42 ° C. for 46 to 48 hours to prepare a culture solution.
이때 배양 용액은 멸균된 대두분말 용액 이외에도 검정 콩파쇄물, MRS 배지 등을 사용할 수 있으며, 바실러스 서브틸리스( Bacillus subtilis ) 균주의 스타터 균을 배양가능한 경우라면 이에 각별히 한정이 있는 것은 아니다. In this case, in addition to the sterilized soybean powder solution, black soy crushed powder, MRS medium, and the like may be used, and Bacillus subtilis ( Bacillus subtilis) may be used. subtilis ) If the starter bacteria of the strain can be cultured is not particularly limited thereto.
그 다음, 멸균된 녹두 첨가 탈지대두박 용액에 배양액을 접종한 후 40~42℃에서 24~26시간 발효시킨다. 배양액의 접종 농도는 1~2% 일 수 있다. Then, after inoculating the culture solution in sterilized mung bean added skim soybean meal solution and fermentation at 40 ~ 42 ℃ for 24 to 26 hours. The inoculation concentration of the culture solution may be 1 to 2%.
이와 같은 방법에 따라 녹두 발효물과 탈지대두박 발효물의 혼합물 용액을 제조할 수 있으며, 이러한 혼합물 용액을 그대로 식품으로 이용할 수 있고, 추가적으로 동결건조 등의 건조공정을 수반하여 동결건조물 형태로 식품으로 이용할 수도 있다. According to the above method, a mixture solution of mung bean fermentation product and skim soybean meal fermentation product may be prepared, and the mixture solution may be used as a food as it is, or may be used as food in the form of a lyophilized product with a drying process such as lyophilization. have.
이하에서는 본 발명의 일 구현예들에 의한 녹두 발효물과 탈지대두박 발효물의 혼합물의 콜레스테롤 및 지질대사 개선을 도모하는 식품으로서의 용도를 뒷받침하기 위한 실험을 수행하고 그 효과를 확인한다.Hereinafter, the experiment to support the use as a food for promoting cholesterol and lipid metabolism of the mixture of mung bean fermentation and skim soybean meal fermentation according to one embodiment of the present invention to confirm the effect.
다만, 이하의 실시예에서 녹두 발효물과 탈지대두박 발효물의 혼합물의 특성 및 효과를 용이하게 대비하기 위하여 탈지대두박 발효물 단독의 경우와도 대비를 수행하나, 이는 다만 탈지대두박 발효물과 녹두 발효물과의 혼합에 따른 효과의 변화를 가늠하기 위한 것일 뿐 탈지대두박 발효물의 콜레스테롤 및 지질대사 개선을 도모하는 식품으로서의 용도가 공지된 것으로 이해되어서는 아니 될 것이다. However, in the following examples, in order to easily prepare for the characteristics and effects of the mixture of mung bean fermented product and skim soybean meal fermentation, a comparison with the case of skim soybean meal fermentation alone is carried out, but this is only for defatted soybean meal fermentation and mung bean fermentation. It is only intended to estimate the change in the effect of the mixing with and the use of the skim soybean meal fermentation as a food to promote the improvement of cholesterol and lipid metabolism should not be understood.
<실시예> <Examples>
1. 시약 및 기기1. Reagents and Instruments
1) 시약1) Reagent
세포배양에 사용된 dulbecco's modified eagle medium (DMEM), fetal bovine serum (FBS), antibiotics, trypsin-EDTA는 Gibco BRL (Gibco BRL, Grand island, N.Y., USA)로부터 구입하였다. Dulbecco's modified eagle medium (DMEM), fetal bovine serum (FBS), antibiotics, and trypsin-EDTA used for cell culture were purchased from Gibco BRL (Gibco BRL, Grand island, N.Y., USA).
콜레스테롤 조절능 측정을 위해 총 콜레스테롤 측정용 kit는 아산제약 (Seoul, Korea)의 제품을 구입하였고, apolipoprotein 분비량 측정을 위해 apolipoprotein-AⅠ, apolipoprotein-AⅡ, apolipoprotein-CⅢ는 Academy Bio-Medical (Huston, USA)과 anti-goat IgG는 Jackson ImmunoResearch Laboratories (West Grove, USA)로부터 구입하였다. Total cholesterol measurement kit was purchased for measurement of cholesterol control ability by Asan Pharmaceutical (Seoul, Korea), and apolipoprotein-AⅠ, apolipoprotein-AⅡ, and apolipoprotein-CIII were used for Academy Bio-Medical ) And anti-goat IgG were purchased from Jackson ImmunoResearch Laboratories (West Grove, USA).
Tyrosine 함량 측정시 이용된 Folin-phenol reagent는 Junsei Chemical Co. (Tokyo, Japan)을 사용하였다. 간의 HMG-CoA reductase 활성측정을 위해 NADPH, HMG-CoA, mevalonlactone은 Sigma (ST. Louis. MO., USA)로부터 구입하여 사용하였다. 그 외 시약 및 유기용매도 일급시약을 사용하여 실험하였다.Folin-phenol reagent used in measuring the tyrosine content is Junsei Chemical Co. (Tokyo, Japan) was used. NADPH, HMG-CoA, mevalonlactone were purchased from Sigma (ST. Louis. MO., USA) for the measurement of HMG-CoA reductase activity of the liver. Other reagents and organic solvents were also tested using first-class reagents.
2) 기기2) appliance
본 실험에 사용된 기기는 UV/visible spectrophotometer (Unikon 922, Kontron, Italy), incubator (Model 3154, Forma Scientific, USA), ultracentrifuge (Model 695-7, Hitachi, Japan), microplate spectrophotometer (Molecular Devices, Spectra max 340PC, USA), microplate shaker (Finemixer SH2000, FINEPCR, Korea), deep freezer (CLN-50VW, Nihon freezer, Japan), glass teflon homogenizer (Glascol, 099C K44, USA), pH meter (model 691, Metrohm, Swiss) 등이다.Instruments used in this experiment were UV / visible spectrophotometer (Unikon 922, Kontron, Italy), incubator (Model 3154, Forma Scientific, USA), ultracentrifuge (Model 695-7, Hitachi, Japan), microplate spectrophotometer (Molecular Devices, Spectra max 340PC, USA), microplate shaker (Finemixer SH2000, FINEPCR, Korea), deep freezer (CLN-50VW, Nihon freezer, Japan), glass teflon homogenizer (Glascol, 099C K44, USA), pH meter (model 691, Metrohm, Swiss).
2. 시료 준비2. Sample Preparation
1) 천연소재 추출물의 조제1) Preparation of natural material extract
본 실험에 사용된 식용가능한 버섯, 향신료, 한방소재 및 녹두를 포함하는 천연물 9종은 Table 1과 같으며, 커리플라워와 녹두는 대형마트에서 구입하였고 커리플라워와 녹두를 제외한 나머지 재료는 대구 약령시장에서 건조된 것을 구입하여 사용하였다. 시료의 불순물을 제거하기 위해 수세하여 건조시킨 후 시료 무게의 10배(w/v)의 80% 메탄올을 가하여 24시간 동안 정치하여 총 3회 반복 추출하였다. 추출액은 여과지 (Whatman No.3, England)를 사용하여 여과한 액을 rotary vacuum evaporator (R-3000, Buchi Switzerland)로 55℃에서 농축한 다음 동결 건조하여 사용하였다. Nine natural products including edible mushrooms, spices, herbal ingredients and mung beans used in this experiment are shown in Table 1, and curry flowers and mung beans were purchased at the hypermarket, and the remaining ingredients except curry flowers and mung beans were Daegu Yangnyeong Market. The dried thing was purchased and used. In order to remove impurities, the sample was washed with water and dried, and 10 times (w / v) of 80% methanol was added thereto, and the mixture was left for 24 hours and extracted three times. The extract was filtered using a filter paper (Whatman No. 3, England) and concentrated using a rotary vacuum evaporator (R-3000, Buchi Switzerland) at 55 ° C., followed by freeze drying.
2) 원료처리 및 발효물 제조2) Raw material processing and fermented product manufacturing
탈지대두박(Defatted Soybean Grit, 이하 DSG라 약칭한다.)은 ADM사 (Decatur, IL, USA)에서 구입하여 사용하였고, 균주로는 (주)NUC전자 바이오연구소의 보유균주인 바실러스 서브틸러스 BN-NUC1(KCCM10839P)을 사용하여 실험하였다. Defatted soybean meal (abbreviated LA Defatted Soybean Grit, hereinafter DSG) is ADM Company (Decatur, IL, USA) by was used, with strains purchased from the (main) NUC holds strain Bacillus sub-blocks scan of the electron Bio Research BN - Experiment using NUC1 (KCCM10839P).
발효물의 제조공정을 도 1을 참조하여 설명하면, 먼저 DSG 단독 발효물을 제조하는 공정은, DSG 원료에 증류수를 원료대비 2.5배 중량비로 첨가한 후 고압 멸균기로 121℃에서 15분간 증자하였다. 증자된 DSG를 실온에서 50∼60℃로 냉각하였다. 한편 멸균된 대두분말 용액에서 B. subtilis BN-NUC1(KCCM10839P)을 40~42℃에서 46~48시간 배양하여 배양액을 얻고, 이를 상기 증자한 DSG 용액에 B. subtilis BN-NUC1(KCCM10839P)이 2%가 되게 접종한 후 40~42℃에서 24~26시간 발효시켜 DSG 발효물(이하, FD라 한다.)을 얻었다. Referring to the manufacturing process of the fermentation with reference to Figure 1, first, the process of producing a single DSG fermentation, the distilled water was added to the DSG raw material 2.5 times the weight ratio of the raw material and then a high-pressure sterilizer for 15 minutes at a steam. The cooked DSG was cooled to 50-60 ° C. at room temperature. On the other hand in a sterile soy flour solution B. subtilis BN - NUC1 gain (KCCM10839P) for 46 ~ 48 hours to the culture medium at 40 ~ 42 ℃, B. subtilis BN at a DSG solution the increase it - NUC1 (KCCM10839P) 2 After inoculating to%, it was fermented at 40-42 ° C. for 24 to 26 hours to obtain a DSG fermented product (hereinafter referred to as FD).
한편, 탈지대두박과 녹두의 혼합 발효물의 제조는, 먼저 DSG 원료에 증류수를 원료대비 2.5배 중량비로 첨가한 후 여기에 분말 녹두를 DSG 원료 중량 대비하여 2.5 내지 10중량부 되도록 첨가량을 달리하여 첨가하여 용해시킨 다음, 이를 고압 멸균기로 120~121℃에서 15~16분간 증자한 후 냉각하였다. Meanwhile, in the preparation of the mixed fermentation product of skim soybean meal and mung beans, first, distilled water is added to the DSG raw material at 2.5 times the weight ratio, and then the powdered green soybean is added by varying the amount of 2.5 to 10 parts by weight based on the DSG raw material weight. After dissolving, the mixture was cooked in a high pressure sterilizer at 120-121 ° C. for 15-16 minutes and then cooled.
한편 멸균된 대두분말 용액에서 B. subtilis BN-NUC1(KCCM10839P)을 40~42℃에서 46~48시간 배양하여 배양액을 얻고, 이를 상기 증자한 녹두 첨가 DSG 용액에 B. subtilis BN-NUC1(KCCM10839P)이 2%가 되게 접종한 후 40~42℃에서 22~24시간 발효시켜 녹두 첨가 DSG 발효물(이하, FDM이라 한다.)을 얻었다. Meanwhile, B. subtilis BN - NUC1 (KCCM10839P) was incubated at 40-42 ° C. for 46-48 hours in a sterilized soybean powder solution to obtain a culture medium, which was then added to B. subtilis BN - NUC1 (KCCM10839P). After inoculation to 2%, fermentation was carried out at 40 to 42 ° C. for 22 to 24 hours to obtain a mung bean-added DSG fermentation product (hereinafter referred to as FDM).
각각의 발효물을 동결건조하여 이하의 실험에 이용하였다. Each fermentation was lyophilized and used for the following experiment.
3.3. In vitro In vitro system을 이용한 콜레스테롤 조절능 검색 Cholesterol Regulatory Capability by Using System
1) 총 콜레스테롤 흡착능1) Total cholesterol adsorption capacity
총 콜레스테롤 흡착능 측정은 효소법에 의한 아산제약 총콜레스테롤 측정용 kit (AM 202-K)를 사용하여 측정하였다. 동결건조한 발효물을 10배의 증류수에 녹인 후 발효물 1 mL에 30 μg의 콜레스테롤을 첨가하여 25℃에서 20분 동안 잘 섞어준 후, 0.1 M hexadecyltrimethylamminium bromide을 50 μL를 가하여 섞은 후 4℃에서 15,000 rpm으로 10분간 원심분리하여 상층액을 취해 효소액과 37℃에서 5분간 반응시킨 뒤 500 nm에서 흡광도를 측정하였다(Soh, H. S.; Kim, C. S.; Lee, S. P. A new in vitro assay of cholesterol adsorption by food and microbial polysaccharides J. Med. Food. 2003, 6, 225-230. 참조).Total cholesterol adsorption capacity was measured using Asan Pharmaceutical Total Cholesterol Kit (AM 202-K) by enzyme method. The lyophilized fermented product was dissolved in 10-fold distilled water, and 30 μg of cholesterol was added to 1 mL of the fermented product, and the mixture was mixed well at 25 ° C. for 20 minutes. After centrifugation for 10 minutes at rpm, the supernatant was taken, reacted with enzyme solution for 5 minutes at 37 ° C, and absorbance was measured at 500 nm (Soh, HS; Kim, CS; Lee, SP A new in vitro assay of cholesterol adsorption by food). and microbial polysaccharides J. Med. Food. 2003, 6, 225-230.
2) HMG-CoA reductase 저해활성2) HMG-CoA reductase inhibitory activity
간 조직의 효소원은 Hulcher 등의 방법(Hulcher, F.; Oleson, W. H. Simplified spectrophotometric assay for microsomal HMG-CoA reductase by measurement of coenzyme A. J. Lipid Res. 1973, 14, 625-631. 참조)을 일부 수정하여 분리하였다. 적출한 간 조직 1 g당 4배량의 0.1 M potasium phosphate (pH 7.4)를 가한 후 마쇄하여 4℃ 이하에서 600×g로 10분간 원심분리한 다음 상층액을 취해, 이를 10,000×g, 4℃에서 20분간 원심분리하였다. 상층액을 다시 105,000×g, 4℃ 1시간 동안 초원심분리하여 침전물인 microsomal 분획을 얻어 사용하였다. 분획은 일정량씩 나누어 실험에 사용할 때까지 80℃에서 보관하였다. Enzyme sources of liver tissue are described by Hulcher et al. (Hulcher, F .; Oleson, WH Simplified spectrophotometric assay for microsomal HMG-CoA reductase by measurement of coenzyme A. J. Lipid Res. 1973, 14, 625-631. And some modifications). 4 g of 0.1 M potasium phosphate (pH 7.4) was added per g of isolated liver tissue, ground and centrifuged at 600 × g for 10 min at 4 ° C or below, and then the supernatant was collected. Centrifuged for 20 minutes. The supernatant was again used for ultrasomal separation at 105,000 × g, 4 ° C. for 1 hour to obtain a microsomal fraction as a precipitate. Fractions were stored at 80 ° C. until used in experiments in portions.
측정 방법은 1 mL cuvette에 시료 20 μL, 0.5 mM phosphate buffer (pH 7.0), 20 mM DTT 100 μL, 3 mM NADPH 100 μL, 효소원 100 μL를 넣었다. 반응액의 온도는 37℃로 일정하게 유지하여 약 10분간 preincubation한 후에 3 mM HMG-CoA 100 μL를 가하여 효소 반응을 시작하였다. 반응이 시작됨과 동시에 340 nm에서 5분간의 흡광도 변화를 기록하였다. HMG-CoA reductase의 억제활성은 다음 식에 의하여 계산하였다. In the measurement method, 20 μL of a sample, 0.5 mM phosphate buffer (pH 7.0), 20 μm DTT 100 μL, 3
HMG-CoA reductase inhibition activity (%) = HMG-CoA reductase inhibition activity (%) =
T: △O.D. of sample C: △O.D. of blank T: ΔO.D. of sample C: ΔO.D. of blank
3) 세포 배양3) cell culture
본 실험에 사용한 인간 유래의 간암 세포주인 HepG2는 한국 세포주은행으로부터 분양 받았으며, 10% FBS와 1% antibiotics를 첨가한 DMEM (Dulbecco's modified eagle medium) 배지를 이용하여 5% CO2가 존재하는 37℃ incubator에서 2일에 한번씩 계대 배양하였다. HepG2, a human-derived liver cancer cell line used in this experiment, was distributed from Korea Cell Line Bank, and 37 ° C incubator containing 5% CO 2 using DMEM (Dulbecco's modified eagle medium) medium containing 10% FBS and 1% antibiotics. Passage was incubated once every two days.
4) 세포주를 이용한 총 콜레스테롤 함량 측정4) Determination of Total Cholesterol Content Using Cell Lines
세포주를 이용한 총 콜레스테롤 함량 측정은 Park등의 방법(Park, S. C.; Noh, Y. H.; Koo, J. H. Effect of ginseng componets on content of cholesterol and activity of Acyl CoA : Cholesterol Acyltransferase in Hep G2 cells cultured in cholesterol rich medium. Korean J. Ginseng Sci. 1995, 19, 212-218. 참조)을 일부 수정하여 HepG2 세포를 6-well plate(corning, USA)에 DMEM (FBS 2%) 배지에 5×105 cell/mL로 분주하고 24시간 배양하여 이를 PBS로 세척한 후 10 μg/mL의 콜레스테롤이 함유되어 있는 DMEM (FBS 0%) 배지에 추출물을 각각 첨가하여 8시간 배양하였다. 그 후 상층액을 취한 다음 1% 에탄올을 함유하는 PBS로 세포를 1회 세척하고 다시 에탄올이 첨가되지 않은 PBS로 세포를 3회 세척한 후 lysis 시켜 총 콜레스테롤 함량을 효소법에 의한 아산제약 총콜레스테롤 측정용 kit (AM 202-K)를 사용하여 흡광도를 측정하였고, 단백질은 Lowry 법(Lowry, O. H.; Rosebrough, N. H.; Farr, A. L.; Randall, R. J. Protein measurement with folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275. 참조)으로 정량하여 콜레스테롤 양을 산출하였다. The total cholesterol content using cell lines was measured by Park et al. (Park, SC; Noh, YH; Koo, JH Effect of ginseng componets on content of cholesterol and activity of Acyl CoA: Cholesterol Acyltransferase in Hep G2 cells cultured in cholesterol rich medium. Korean J. Ginseng Sci. 1995 , 19, 212-218. HepG2 cells were aliquoted into 5 × 10 5 cells / mL in DMEM (
5) Apolipoprotein 분비능 검색5) Apolipoprotein secretion search
Apolipoprotein의 분비능은 enzyme-linked immunosorbent 법(Sambrook, J.; Russell, D. W. Molecular Cloning : A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press. 2001. 참조)으로 검색하였다. 먼저, HepG2 세포를 high glucose DMEM 배지에 5×105 cell/mL로 분주하고 시료를 처리한 뒤 24시간 후에 배양액을 96-well plate (Corning, USA)에 50 μl/well로 분주하고 4℃에 방치하였다. 12시간 후 5% skim milk에 37℃에서 1시간동안 배양한 다음 1차 항체와 2차 항체를 반응시켰다. 마지막으로 발색시약인 1,2-pheylenediamine(100 μl/well)에 30분간 반응시킨 후 492 nm에서 흡광도를 측정하였다. Apolipoprotein secretion was detected by enzyme-linked immunosorbent method (Sambrook, J .; Russell, DW Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press. 2001. ). First, HepG2 cells were dispensed at 5 × 10 5 cells / mL in high glucose DMEM medium, and after 24 hours of treatment, the cultures were dispensed at 50 μl / well in a 96-well plate (Corning, USA) at 4 ° C. It was left to stand. After 12 hours, incubated for 1 hour at 37 ° C. in 5% skim milk, and the first and second antibodies were reacted. Finally, after reacting with the
4. 발효물의 이화학적 특성분석4. Physicochemical Characterization of Fermented Products
1) pH 측정1) pH measurement
pH는 시료 20 g을 채취하여 80 mL의 증류수에 용해한 후 pH meter를 이용하여 측정하였다. pH was measured using a pH meter after taking 20 g of the sample and dissolved in 80 mL of distilled water.
2) Tyrosine 함량 측정2) Tyrosine content measurement
발효물의 peptide 생성정도를 측정하기 위하여 Folin phenol 시약을 이용하여 발효물 중에 존재하는 tyrosine 함량을 측정하였다(Matsushita, S.; Iwami, N.; Nitta, Y. Colorimetric estimation of amino acids and peptides with the Folin phenol reagent. Anal. Biochem. 1966, 16, 365-371. 참조). 각 발효물을 증류수로 5배 희석하여 추출한 시료액 0.7 mL에 0.44 M TCA (trichloroacetic acid) 0.7 mL을 첨가하여 37℃에서 30분간 반응시킨 다음, 15,000 rpm에서 10분동안 원심 분리하여 침전물을 제거하였다. 회수된 상층액 1 mL에 0.55 M Na2CO3 2.5 mL와 phenol reagent 0.5 mL를 차례로 넣고 혼합한 후 37 ℃ 항온수조에서 30분간 반응시켰다. 상온에서 냉각시킨 후 반응액의 흡광도를 spectrophotometer로 660 nm에서 측정하였다.In order to measure the degree of peptide production of fermented products, the content of tyrosine in fermented products was measured using Folin phenol reagent (Matsushita, S .; Iwami, N .; Nitta, Y. Colorimetric estimation of amino acids and peptides with the Folin phenol reagent.Anal. Biochem . 1966, 16, 365-371. 0.7 mL of 0.44 M TCA (trichloroacetic acid) was added to 0.7 mL of the sample solution diluted five-fold with distilled water and reacted at 37 ° C. for 30 minutes, followed by centrifugation at 15,000 rpm for 10 minutes to remove the precipitate. . 2.5 mL of 0.55 M Na 2 CO 3 and 0.5 mL of phenol reagent were sequentially added to 1 mL of the recovered supernatant, followed by reaction for 30 minutes in a 37 ° C. constant temperature water bath. After cooling at room temperature, the absorbance of the reaction solution was measured at 660 nm with a spectrophotometer.
3) 가수분해 효소활성도 측정3) Determination of hydrolase activity
효소활성은 α-amylase와 protease로 나뉘어 역가를 측정하였으며, 발효물 5 g에 0.02 M phosphate buffer (pH 7.0) 95 mL을 첨가한 뒤 실온에서 진탕 후 원심분리(15,000 rpm, 15 min)하여 상층액으로부터 효소액을 조제한 다음 효소활성을 측정하였다. α-amylase의 기질로는 1% 가용성전분 (0.02 M phosphate buffer, pH 7.0) 1 mL을 사용하였다. 미리 조제한 효소액을 1 mL 첨가하여 37℃에서 30분간 반응시킨 후 1 M acetic acid 10 mL로 반응을 정지시키고 요오드화 용액 (0.005% I2 + 0.05% KI) 2 mL을 넣고 발색시킨 후 660 nm에서 흡광도를 측정하여 blank OD값을 10% 감소시키는 것을 1 unit로 하여 시료 1 g 으로 환산 시킨 후 표시하였다. 대조군인 공시험은 미리 제조한 효소액을 100℃에서 30분간 끓여서 불활성화시킨 검액을 사용하였다(Park, J. M.; Oh, H. I. Changes in microflora and enzyme activities of traditional Kochujang meju during fermentation. Korean J. Food Sci. Technol. 1995, 27, 56-62. 참조). Enzyme activity was divided into α-amylase and protease to measure the titer. After adding 95 mL of 0.02 M phosphate buffer (pH 7.0) to 5 g of fermentation, the mixture was shaken at room temperature and centrifuged (15,000 rpm, 15 min). The enzyme solution was prepared from and the enzyme activity was measured. 1 mL of 1% soluble starch (0.02 M phosphate buffer, pH 7.0) was used as a substrate of α-amylase. After adding 1 mL of the prepared enzyme solution and reacting at 37 ° C. for 30 minutes, the reaction was stopped with 10 mL of 1 M acetic acid, added with 2 mL of iodide solution (0.005% I 2 + 0.05% KI), and then absorbed at 660 nm. Was measured and the blank OD value was reduced by 10% to 1 unit and converted into 1 g of sample. In the blank test as a control, a sample solution prepared by inactivating a previously prepared enzyme solution by boiling it at 100 ° C. for 30 minutes was used (Park, JM; Oh, HI Changes in microflora and enzyme activities of traditional Kochujang meju during fermentation.Korean J. Food Sci.Technol 1995, 27, see 56-62).
Protease의 활성도는 Anson의 방법(Kim, H. J.; Lee, J. J.; Cheigh, M. J.; Choi, S. Y. Amylase, protease, peroxidase and ascorbic acid oxidase activity of Kimchi ingredients. J. Food Sci. Technol. 1998, 30, 1333-1338. 참조)을 변형하여 측정하였다. 기질로 0.6%의 casein용액 0.35 mL와 효소액 0.35 mL를 e-tube에 넣고 항온수조에서 반응(37℃, 10 min)시킨 다음 0.44 M TCA 용액 0.7 mL을 넣어 반응을 정지시킨 후 37℃에서 30분간 정치시켰다. 이 반응액을 원심분리(15,000 rpm, 15 min)한 후 여액 1 mL와 0.55 M Na2CO3 2.5 mL, 3배 희석된 Folin reagent 0.5 mL을 넣고 37℃에서 30분간 반응시킨 후 660 nm에서 흡광도를 측정하였다. 이 반응조건 하에서 1분간에 tyrosine 1 ug을 유리시키는 효소량을 1 unit로 하였다.The activity of protease was determined by Anson's method (Kim, HJ; Lee, JJ; Cheigh, MJ; Choi, SY Amylase, protease, peroxidase and ascorbic acid oxidase activity of Kimchi ingredients.J. Food Sci. Technol. 1998, 30, 1333- 1338.). Add 0.35 mL of 0.6% casein solution and 0.35 mL of enzyme solution to the e-tube as a substrate, and react in a constant temperature water bath (37 ℃, 10 min), stop the reaction by adding 0.7mL of 0.44 M TCA solution, and stop at 37 ℃ for 30 minutes. Let it stand. Centrifuge the reaction solution (15,000 rpm, 15 min), add 1 mL of filtrate, 2.5 mL of 0.55 M Na 2 CO 3 , and 0.5 mL of 3-fold diluted Folin reagent, react for 30 minutes at 37 ℃, and absorbance at 660 nm. Was measured. Under this reaction condition, the amount of enzyme that liberates 1 ug of tyrosine in 1 minute was 1 unit.
4) 점조도 측정4) consistency measurement
시료 발효물 5 g에 증류수 45 mL 첨가하여 균질화 후에 여과체 (sieve, 0.99 mm)를 이용하여 여과시킨 시료를 제조하였다. 여과액 13 mL을 취하여 원통형점도계(HAAKE RheoStress 1, Germany)에 spindle(Rotor DG43 DIN 53544 Titan, Germany)을 장착하여 measuring cup DG43을 사용하여 측정하였다. 측정온도는 20℃에서 전단속도(γ)는 1-100 s-1의 범위에서 점도 측정을 통해서 유동특성을 알아보았고, 점조도 지수는 power law model로 측정하였다(46). 45 mL of distilled water was added to 5 g of the sample fermentation product, and homogenized to prepare a sample filtered using a sieve (sieve, 0.99 mm). 13 mL of the filtrate was taken and measured using a measuring cup DG43 by mounting a spindle (Rotor DG43 DIN 53544 Titan, Germany) on a cylindrical viscometer (
Power law model : σ = K·γn Power law model: σ = K · γ n
σ는 전단응력(Pa), K는 점조도 지수(consistency index, Pa·sn), γ는 전단속도(s-1), n은 유동성 지수(flow behavior index)이다.σ is the shear stress (Pa), K is the consistency index (Pa · s n ), γ is the shear rate (s -1 ), and n is the flow behavior index.
5) 점질물 함량 측정5) Determination of Viscous Content
시료에 5 g에 증류수를 첨가하여 균질화시킨 후 여과체를 이용하여 여과시킨 후 10,000 rpm에서 20분간 원심분리하여 상층액을 취하였다. 회수한 상층액에 2배 부피의 iso-propanol을 첨가하여 고형분을 침전시킨 후 고형분을 회수하여 80% 에탄올로 세척한 후 60∼70℃ 진공열풍건조기에서 하루 동안 건조한 후 건조무게를 측정하였다(47). Distilled water was added to 5 g of the sample, homogenized, filtered using a filter medium, and centrifuged at 10,000 rpm for 20 minutes to obtain a supernatant. Solids were precipitated by adding 2 times the volume of iso-propanol to the recovered supernatant, and then the solids were recovered, washed with 80% ethanol and dried in a vacuum hot air dryer at 60-70 ° C. for one day. ).
5. 5. In vivoIn vivo system을 이용한 지질대사 및 콜레스테롤 개선능 검색 Screening of Lipid Metabolism and Cholesterol Improvement Using System
1) 동물실험 계획 및 실험식이 조성1) Animal test plan and experimental diet
실험동물은 (주)오리엔트사 (Pusan, Korea)로부터 5주령 (100∼150 g)의 Sprague-Dawley종 수컷 랫트 24마리를 구입하여 사용하였다. 사육실 온도는 23 ± 2℃, 상대습도는 60 ± 5%를 유지시키고, 12시간 주기로 명암이 유지되는 사육실에서 사육하였다. 처음 1주일간 pellet형의 lab chow 식이를 제공하면서 적응시킨 후, 난괴법 (randomized block design)에 의해 4개의 군으로 나누었다.The experimental animals were purchased from Orient Co., Ltd. (Pusan, Korea) 24 rats of Sprague-
실험식이는 표 2에 제시된 바와 같이 정상 식이군 (CON군), 고지방 식이군 (HF군), 고지방 식이에 20% FD을 첨가한 군 (HF-FD군), 고지방식이에 20% FDM을 첨가한 군 (HF-FDM군)으로 나누어 4주간 사육하였다. 각 군별 6 마리의 랫트를 사용하였고, 고지방 식이는 10% lard, 1% cholesterol 그리고 0.25% sodium cholate를 기본식이에 첨가하여 공급하였다. 실험식이의 조성은 다음 표 3과 같으며, 이때 음용수와 사료는 충분한 양을 공급하였다. As shown in Table 2, the experimental diet was divided into the normal diet group (CON group), the high fat diet group (HF group), the high fat diet group with 20% FD (HF-FD group), and the high fat diet with 20% FDM. It was divided into the added group (HF-FDM group) and reared for 4 weeks. Six rats of each group were used, and a high fat diet was supplied by adding 10% lard, 1% cholesterol and 0.25% sodium cholate to the basic diet. The composition of the experimental diet is shown in Table 3, where drinking water and feed were supplied in sufficient amounts.
1)고지방 식이는 정상 식이에 1% 콜레스테롤, 10% lard, 0.25% 소듐 콜레이트를 포함시킴. 1) High fat diets include 1% cholesterol, 10% lard, 0.25% sodium cholate in the normal diet.
2)DSG 100중량부에 대하여 2.5중량부에 해당하는 양의 분말 녹두를 첨가하여 얻어지는 발효물 2) Fermented product obtained by adding 2.5 parts by weight of powder mung beans to 100 parts by weight of DSG.
aStarch와 bcasein은 FD와 FDM 분말 중의 프로테인과 카보하이드레이트 함량에 의해 조정되었다. a Starch and b casein were adjusted by the protein and carbohydrate content in the FD and FDM powders.
2) 실험동물 처리 및 시료수집2) Experiment animal treatment and sample collection
식이 섭취량은 일주일에 한 번 식이 잔량을 측정하여 식이 제공량으로부터 뺀 값으로 계산하였으며, 체중은 매주 일정한 시간에 측정하였다. 또한 사육기간 마지막 3일간은 분변을 수집하여 건조시킨 후 냉동보관 하였다. The dietary intake was calculated by subtracting the dietary amount from the dietary amount once a week, and the weight was measured at a certain time every week. In the last three days of the breeding period, the feces were collected, dried, and stored frozen.
사육기간 동안의 혈액 내 지질 및 콜레스테롤 변화를 관찰하기 위해 사육 전, 사육 2주째에 각각 쇄골 대정맥채혈 방법으로 혈액을 채취해 원심 분리하여 혈장을 분리하였다. 분리한 혈장은 자동혈액분석기로 지질 및 콜레스테롤 농도를 측정하였다. In order to observe the lipid and cholesterol changes in the blood during the breeding period, blood was collected by the clavicle venous blood collection method before the breeding, and the plasma was separated by centrifugation. The separated plasma was measured for lipid and cholesterol concentrations using an automatic blood analyzer.
4주간의 사육이 끝난 다음 12시간 절식시킨 랫트를 에테르로 마취시켜 해부하였다. 복부대동맥으로부터 헤파린 처리된 주사기로 혈액을 채취하여, 30분 동안 방치한 후 3,000 rpm에서 15분간 원심 분리하여 혈장을 분리하였다. 또한 간, 신장, 비장과 부고환지방, 복부지방도 적출하여 생리식염수에 헹군 후 물기를 제거하고 칭량하였다. 분리된 혈장 및 조직들은 액체질소로 급냉하여 분석시까지 -70℃에 보관하였다. 분리한 혈장은 중성지질 및 콜레스테롤 함량 측정에 사용하였고, 간 조직은 지질 함량 및 간 내 효소활성 측정에 사용하였다. Rats fasted 12 hours after 4 weeks of breeding were anaesthetized with ether. Blood was collected from the abdominal aorta with a heparinized syringe, left for 30 minutes, and centrifuged at 3,000 rpm for 15 minutes to separate plasma. In addition, liver, kidney, spleen, epididymal fat, and abdominal fat were also extracted, rinsed with saline, and then drained and weighed. The separated plasma and tissues were quenched with liquid nitrogen and stored at -70 ° C until analysis. The separated plasma was used to measure neutral lipid and cholesterol content, and liver tissue was used to measure lipid content and enzyme activity in liver.
3) 혈장의 중성지질 및 콜레스테롤 함량 분석3) Analysis of triglyceride and cholesterol content in plasma
주차별로 분리한 혈장의 총 콜레스테롤, 중성지질, HDL-콜레스테롤, LDL-콜레스테롤함량은 자동혈액분석기로 측정하였다. 이때 혈청 중의 중성지방은 중성지방 측정용 kit, 총콜레스테롤 함량은 총콜레스테롤 측정용 kit, HDL-콜레스테롤 함량은 HDL-콜레스테롤 측정용 kit를 각각 사용하여 측정하였다.Total cholesterol, triglyceride, HDL-cholesterol and LDL-cholesterol content of plasma separated by parking lot were measured by automatic blood analyzer. At this time, the triglyceride in serum was measured using a kit for measuring triglyceride, total cholesterol content kit for total cholesterol content, and HDL-cholesterol content kit for HDL-cholesterol content.
LDL-콜레스테롤은 분석을 통해 얻은 총 콜레스테롤, HDL-콜레스테롤 그리고 중성지방의 수치를 이용하여 아래의 계산식에 의해 계산하였다(Friedewald, W. T.; Levy, R. I.; Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, with out use of the preparative ultracentrifuge. Clin. Chem. 1972, 18: 499-502 참조). LDL-cholesterol was calculated by the following formula using the values of total cholesterol, HDL-cholesterol and triglyceride obtained from the analysis (Friedewald, WT; Levy, RI; Fredrickson, DS Estimation of the concentration of low-density lipoprotein). cholesterol in plasma, with out use of the preparative ultracentrifuge. Clin. Chem. 1972 , 18: 499-502).
LDL-cholesterol = T-cholesterol - (HDL-cholesterol + TG/5) LDL-cholesterol = T-cholesterol-(HDL-cholesterol + TG / 5)
4) 간내 HMG-CoA reductase 활성 분석4) Intrahepatic HMG-CoA reductase Activity Assay
적출한 간조직 1 g당 4배량의 0.1 M potassium phosphate (pH 7.4)을 가한 후 마쇄하여 4℃ 이하에서 600×g로 10분간 원심분리한 다음 상층액을 취해 이를 4℃에서 10,000×g로 20분간 원심분리하였다. 상층액을 다시 4℃에서 105,000×g로 1시간 동안 초원심분리하여 침전물인 microsomal 분획을 측정에 사용하였다. HMG-CoA reductase 활성 측정은 Hulcher의 방법(Hulcher, F.; Oleson, W. H. Simplified spectrophotometric assay for microsomal HMG-CoA reductase by measurement of coenzyme A. J. Lipid Res. 1973, 14, 625-631. 참조)을 변형하여 사용하였다. 150 μM HMG-CoA와 2 mM NADPH를 500 μg microsome 분획과 잘 섞은 후 0.1 M triethanolamine, 0.02 M EDTA (pH 7.4) 완충용액으로 1 mL를 채우고 37℃에서 30분간 반응시켰다. 그 다음 0.01 M sodium arsenite 20 μL를 넣고 상온에서 1분 이상 반응시킨 후 100 μL의 2 M citrate (pH 3.5), 3% Na-tungstate 완충용액을 넣고 37℃에서 10분간 반응시켰다. 반응물을 4℃에서 13,000 rpm으로 10분간 원심분리한 후 상층액 1 mL에 200 μL의 2 M Tris (pH 10.6)와 100 μL 2 M Tris (pH 8.0)를 섞어 실온에서 3분간 반응 시킨 후 20 μL의 3 mM 5,5-dithiobis 2-nitrobenzoic acid (DTNB), 0.1 M triethanolamine, 0.2 M EDTA (pH 7.4) 완충용액을 넣고 잘 섞은 후 412 nm에서 4분간의 흡광도 변화를 측정하였다. 이때 효소활성도는 1분간 1 mg의 microsome 단백질이 생성하는 CoA-SH의 양을 nmole로 나타내었다. 그리고 단백질 정량은 Lowry 등의 방법(Lowry, O. H.; Rosebrough, N. H.; Farr, A. L.; Randall, R. J. Protein measurement with folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.)에 의하여 bovine serum albumin을 표준단백질 용액으로 이용한 표준 검량선을 구하여 그 양을 산출하였다.4 g of 0.1 M potassium phosphate (pH 7.4) is added per 1 g of extracted liver tissue, ground and centrifuged at 600 × g for 10 min at 4 ° C or below, and the supernatant is taken. Centrifuged for a minute. The supernatant was ultracentrifuged again at 105,000 × g for 1 hour at 4 ° C., and the precipitate microsomal fraction was used for the measurement. HMG-CoA reductase activity was measured by Hulcher's method (Hulcher, F .; Oleson, WH Simplified spectrophotometric assay for microsomal HMG-CoA reductase by measurement of coenzyme A. J. Lipid Res. 1973, 14, 625-631. ) Was used. After mixing 150 μM HMG-CoA and 2 mM NADPH with 500 μg microsome fraction, 1 mL was charged with 0.1 M triethanolamine, 0.02 M EDTA (pH 7.4) buffer and reacted at 37 ° C. for 30 minutes. Then, 20 μL of 0.01 M sodium arsenite was added and reacted at room temperature for 1 minute or longer. Then, 100 μL of 2 M citrate (pH 3.5) and 3% Na-tungstate buffer solution were added and reacted at 37 ° C. for 10 minutes. The reaction was centrifuged at 13,000 rpm for 10 minutes at 4 ° C, and 200 μL of 2 M Tris (pH 10.6) and 100 μL 2 M Tris (pH 8.0) were mixed in 1 mL of the supernatant and reacted for 3 minutes at room temperature. 3
5) 간 조직의 지질 분석5) Lipid analysis of liver tissue
간 조직 지질의 추출법과 중성지질 및 콜레스테롤 농도 측정법은 Folch 등(49)의 방법과 Sale 등(Sale, F. O.; Marchesine, S. P.; Fishman, H.; Berra, B. A. Sensitive enzymatic assay for determination of cholesterol in lipid extracts. Anal. Biochem. 1984, 347-350. 참조)에 의해 수정, 보완된 방법을 이용하여 측정하였다. Extraction of liver tissue lipids and determination of neutral lipids and cholesterol concentrations were performed by Folch et al. (49) and Sale et al. (Sale, FO; Marchesine, SP; Fishman, H .; Berra, BA Sensitive enzymatic assay for determination of cholesterol in lipid extracts). Anal. Biochem. 1984 , 347-350.).
간 조직 0.5 g을 잘게 자른 후 10 mL의 Folch solution (chloroform : methanol, 2 : 1, v/v)을 첨가하여 조직의 지질을 추출하였다. 추출액은 Whatman 여과지(No. 2)로 여과된 간 추출액과 0.5% H2SO4 3 mL를 분별 깔대기에 넣어 혼합하였다. 일정시간 방치하여 분리된 하층을 새로운 tube에 넣고 총량이 10 mL가 되도록 Folch solution을 첨가하였다. 이 추출액 10 μL를 중성지방 분석에 이용하였다. 10 mL 추출물 500 μL를 새로운 tube에 넣어 하루 밤 동안 실온에서 건조시킨 후 50 μL Triton X-100 : chloroform solution (1 : 1, v/v)을 첨가하여 vortex하고 chloroform 450 μL를 넣어 총 500 μL가 되게 희석하였다. Triton X-100은 chloroform에 용해된 조직지질의 발색시 발생하는 혼탁성을 제거하기 위하여 사용하였으며, 이 용액 10 μL를 간 콜레스테롤 측정에 사용하였다. 간 콜레스테롤과 중성지방 분석은 위 추출액 10 μL를 실온에서 건조 시킨 후 효소액 1.5 mL를 넣고 37℃ water bath에서 10분 간 반응시켜 발색 시킨 후, 콜레스테롤은 500 nm에서 중성지질은 550 nm에서 각각 측정하였다. 0.5 g of liver tissue was chopped and 10 mL of Folch solution (chloroform: methanol, 2: 1, v / v) was added to extract lipids from the tissue. The extract was mixed with liver extract filtered with Whatman filter paper (No. 2) and 0.5 mL H 2 SO 4 3 mL in a separatory funnel. After leaving for a certain time, the separated lower layer was placed in a new tube, and Folch solution was added so that the total amount was 10 mL. 10 μL of this extract was used for triglyceride analysis. 500 μL of 10 mL extract was added to a new tube and dried at room temperature overnight. Then, 50 μL of Triton X-100: chloroform solution (1: 1, v / v) was added to vortex and 450 μL of chloroform was added. Diluted. Triton X-100 was used to remove turbidity caused by the development of tissue lipid dissolved in chloroform. 10 μL of this solution was used to measure liver cholesterol. For liver cholesterol and triglyceride analysis, 10 μL of gastric extract was dried at room temperature, 1.5 mL of enzyme solution was added, and the resultant was reacted for 10 minutes in a water bath at 37 ° C., and cholesterol was measured at 500 nm and neutral lipid at 550 nm. .
6) 분변 중의 지질 함량 측정6) Determination of lipid content in feces
분변 중의 중성지방 및 콜레스테롤은 Folch법(Folch, J.; Lees, M.; Sloane-Stanley, G. H. A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226, 497-509. 참조)으로 추출한 후, 혈장 중성지방은 McGowan 등의 효소법(McGowan, M. W.; Artiss, J. D.; Strandbergh, D. R.; Zak, B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem. 1983, 29: 538-542. 참조)을 이용한 발색법 원리에 따라 측정하였고 혈장 총 콜레스테롤은 Allain 등의 효소법(Allain, C. C.; Poon, L. S.; Chan, C. S. G. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974, 20: 470-475. 참조)을 응용한 아산제약 총콜레스테롤 측정용 kit (AM 202-K)를 사용하여 정량하였다.Triglycerides and cholesterol in feces were determined by the Folch method (Folch, J .; Lees, M .; Sloane-Stanley, GH A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957 , 226, 497 Plasma triglycerides were extracted by McGowan et al. (McGowan, MW; Artiss, JD; Strandbergh, DR; Zak, B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem). 1983, 29: 538-542.) And the plasma total cholesterol was measured according to the enzyme method (Allain, CC; Poon, LS; Chan, CSG Enzymatic determination of total serum cholesterol.Clin. Chem). 1974, 20: 470-475, see) was quantitated using the application in a Asan pharmaceutical total cholesterol measurement kit (AM 202-K).
7) 간과 복부지방 및 부고환지방의 병리학적 변화 관찰7) Observation of pathological changes in liver, abdominal fat and epididymal fat
실험 동물의 조직의 병리학적 변화를 관찰하기 위하여 각 군의 간, 복부지방 및 부고환지방의 일부분을 떼어내 10% neutral buffered formalin에서 24 시간 동안 고정한 후 자동 파라핀 침투기를 이용하여 탈수, 투명 및 침투 과정을 진행하여 파라핀에 포맷한 다음 회전형 박절기를 사용하여 4 μm 두께의 파라핀 절편을 제작하였다. 파라핀 절편은 xylene에 탈파라핀하고 하강 계열 알코올 과정을 진행하여 함수한 후, hematoxylin-eosin (H&E) 염색을 하였다. 염색이 끝난 절편은 탈수 및 투명 과정을 거쳐 카나다 발삼으로 봉입하여 광학 현미경으로 관찰하였다. To observe the pathological changes in the tissues of the experimental animals, a portion of the liver, abdominal and epididymal fats of each group were removed, fixed in 10% neutral buffered formalin for 24 hours, and then dehydrated, clear and infiltrated using an automatic paraffin infiltrator. After proceeding to format the paraffin, using a rotary cutting machine to prepare a paraffin section of 4 μm thickness. Paraffin sections were deparaffinized to xylene and functioned by descending alcohol, followed by hematoxylin-eosin (H & E) staining. After staining, the sections were dehydrated and cleared and encapsulated with Canadian balsam and observed under an optical microscope.
8) 통계분석8) Statistical Analysis
실험결과는 SAS program(53)을 이용하여 분산 분석한 후 유의차가 있는 항목에 대해서는 Duncan's multiple range test로 p<0.05 수준에서 시료간의 유의차를 검정하였다. The experimental results were analyzed by variance analysis using SAS program (53) and then tested for significant differences between samples at p <0.05 level by Duncan's multiple range test.
상기와 같은 방법으로 수행되는 다양한 검색 및 측정의 결과를 고찰하면 다음과 같다. Looking at the results of the various search and measurement performed by the above method as follows.
1. One. In vitroIn vitro system을 이용한 콜레스테롤 조절능 검색 Cholesterol Regulatory Capability by Using System
1) 천연물의 HMG-CoA reductase 저해활성 1) HMG-CoA reductase inhibitory activity of natural products
콜레스테롤 및 지질대사 개선효과를 증진시키기 위해 DSG 발효 시 첨가할 천연물의 선정을 위하여 콜레스테롤 저하능이 있다고 알려져 있는 천연물 9종에 대해서 콜레스테롤 합성계에서 중요한 조절 효소로 작용하는 HMG-CoA reductase의 저해능을 검색해 보았다. In order to improve cholesterol and lipid metabolism, we investigated the inhibitory ability of HMG-CoA reductase, which acts as an important regulatory enzyme in cholesterol synthesis system, for nine natural products known to lower cholesterol for selection of natural products to be added during DSG fermentation.
선정된 9종의 천연물을 80% 메탄올로 추출한 후 100 mg/mL의 농도로 처리하여 HMG-CoA reductase의 저해능을 검색한 결과는 도 2와 같이 선정된 천연물 9종 모두 70% 이상의 우수한 저해능을 보였고, 특히 식용이 가능하면서 90% 이상의 가장 높은 저해활성을 가지는 녹두(Phaseolus radiatus)를 최종 시료로 선정하였다. As a result of detecting the inhibitory ability of HMG-CoA reductase by extracting nine selected natural products with 80% methanol and treating them at a concentration of 100 mg / mL, all nine selected natural products showed excellent inhibition over 70% as shown in FIG. In particular, the final sample was edible and phaseolus radiatus , which has the highest inhibitory activity of more than 90%.
도 2에 있어서, I는 황금, Ⅱ는 능이버섯, Ⅲ은 커리플라워, Ⅳ는 당귀, Ⅴ는 상황버섯, Ⅵ은 감초, Ⅶ은 치커리, Ⅷ은 몰로키아, Ⅸ은 녹두를 나타낸다. In Fig. 2, I denotes golden, II denotes a mushroom, III denotes a curry flower, IV denotes a donkey, V denotes a situation mushroom, VI denotes a licorice, a thin chicory, a thin Molochia, and a thin green bean.
3) HMG-CoA reductase 저해활성3) HMG-CoA reductase inhibitory activity
HMG-CoA reductase는 콜레스테롤 생합성 단계에서 작용하는 조절 효소로써 스테롤이나 isoprenoid계 화합물의 생합성 경로의 중간단계인 mevalonic acid의 합성을 매개하는 역할을 한다.HMG-CoA reductase is a regulatory enzyme that acts in the cholesterol biosynthesis step and mediates the synthesis of mevalonic acid, an intermediate step in the biosynthetic pathway of sterols and isoprenoid compounds.
시료에 의한 HMG-CoA reductase 저해활성은 도 4에 나타내었다. 이를 참조하면, FD의 경우 약 25%의 저해활성을 나타냈었으며, 녹두를 2.5% 첨가한 FD-Mung bean군에서 약 42%의 가장 높은 저해활성을 나타내었다. 특이하게도 녹두를 5, 10% 첨가한 FD-Mung bean군은 녹두 첨가량이 증가할수록 저해활성이 감소되는 것을 확인하였다. 이러한 결과는, 발효물의 혼합물에 있어서 녹두 발효물 함량은 탈지대두박 발효물 100중량부에 대하여 2.5중량부 이내인 것이 HMG-CoA reductase의 활성 측면에서 유리함을 나타낸다. 이처럼 HMG-CoA reductase의 활성이 억제되면 콜레스테롤 생합성을 억제한다고 알려져 있으므로, FD와 FDM은 우수한 콜레스테롤 합성을 억제하는 소재가 되리라 생각된다. HMG-CoA reductase inhibitory activity by the sample is shown in FIG. Referring to this, the FD showed inhibitory activity of about 25% and the highest inhibitory activity of about 42% in the FD-Mung bean group added with 2.5% green beans. Specifically, the FD-Mung bean group containing 5 and 10% of mung beans showed that the inhibitory activity decreased as the amount of mung beans added increased. These results indicate that the content of mung bean fermentation in the mixture of fermentation is within 2.5 parts by weight based on 100 parts by weight of skim soybean meal fermentation in terms of HMG-CoA reductase activity. In this way, it is known that inhibition of HMG-CoA reductase activity inhibits cholesterol biosynthesis, so FD and FDM are expected to be excellent materials for inhibiting cholesterol synthesis.
4) HepG2 세포주를 이용한 총 콜레스테롤 함량 측정4) Determination of total cholesterol content using HepG2 cell line
HepG2 세포내로 콜레스테롤이 가장 잘 유입되는 조건을 측정한 결과, 콜레스테롤의 농도를 10 μg/mL, 8시간 배양했을 때 세포내 콜레스테롤 유입률이 가장 높은 것으로 나타나 이 조건으로 세포를 배양하였다. As a result of measuring the condition that cholesterol is best introduced into HepG2 cells, when the concentration of cholesterol was incubated at 10 μg / mL for 8 hours, the intracellular cholesterol inflow rate was the highest.
시료에 의한 세포 내 콜레스테롤 함량은 도 5에 나타낸 것과 같다. Intracellular cholesterol content by the sample is as shown in FIG.
이를 참조하여 설명하면, 먼저 콜레스테롤(10 μg/mL)만 투여한 대조군 그리고 실험군은 콜레스테롤 첨가배지(10 μg/mL)에 FD 그리고 녹두를 2.5, 5, 10%로 첨가한 FD-Mung bean을 1 mg/mL의 농도가 되도록 각각 처리해 8시간 배양하여 고콜레스테롤 조건하에서 HepG2 세포내의 콜레스테롤 함량을 조사하였다. 각 배지조건으로 배양한 HepG2 세포 내액의 콜레스테롤을 정량하고 단백질 대비 평균값을 구한 결과, 녹두를 2.5, 5% 첨가한 FD-Mung bean군에서 대조군에 비해 세포내의 콜레스테롤 농도가 유의적으로 낮아지는 것을 확인하였다. 특히 녹두를 2.5% 첨가한 FD-Mung bean군에서 가장 낮은 콜레스테롤 함량을 나타내었다. 즉 녹두를 2.5% 첨가하여 발효시켰을 때 첨가하지 않았을 때 보다 콜레스테롤 조절능이 증가하는 것을 알 수 있었다.Referring to this, first, the control group and the experimental group administered only cholesterol (10 μg / mL) added FD-Mung bean containing 2.5, 5, 10% of FD and mung bean to cholesterol-adding medium (10 μg / mL). Cholesterol content of HepG2 cells was examined under high cholesterol conditions by treating each of them to a concentration of mg / mL for 8 hours. As a result of quantifying cholesterol in HepG2 cells cultured in each medium condition and calculating the average value of protein, FD-Mung bean group containing 2.5 and 5% of mung beans significantly lowered the intracellular cholesterol level compared to the control group. It was. In particular, the lowest cholesterol content was found in the FD-Mung bean group containing 2.5% mung beans. That is, when fermentation was performed by adding 2.5% of green beans, cholesterol control ability was increased than when it was not added.
5) Apolipoprotein AⅠ,Ⅱ 및 CⅢ의 분비능 검색5) Secretion of Apolipoproteins A, II and CIII
혈중 지질상태 개선 측면에서 총콜레스테롤, 특히 LDL 콜레스테롤과 중성지방 농도가 저하되는 것이 바람직하지만 HDL 콜레스테롤의 증가도 매우 중요하다.In terms of improving lipid status in the blood, total cholesterol, especially LDL cholesterol and triglyceride levels are lowered, but the increase in HDL cholesterol is also very important.
Apolipoprotein의 기능은 지방질의 운반과 지단백 구조 유지에 있고, 역할은 지단백 대사에 관여하는 효소들의 활성인자가 되며, 지단백 내 지질이 간, 혈관 벽, 지방조직에 대사되는데 필요한 성분이다(채범석. 지방질대사. 서울대학교 의과대학 생화학교실, 1987, 116. 참조).The function of apolipoprotein is in the transport of fat and maintenance of lipoprotein structure, and its role is an activator of enzymes involved in lipoprotein metabolism, and it is necessary for lipids in lipoproteins to be metabolized to liver, blood vessel wall and adipose tissue. Department of Biochemistry, College of Medicine, Seoul National University, 1987 , 116.).
그 중 apolipoprotein AⅠ은 chylomicron과 HDL 콜레스테롤을 구성하는 중요한 지단백일 뿐만 아니라 LCAT를 활성화시키는 작용이 있으며, apolipoprotein AⅡ는 HDL 콜레스테롤의 중요한 구성 단백질이다(58). 특히 apolipoprotein AⅠ과 apolipoprotein AⅡ의 증가는 항동맥경화증의 역할을 하는 HDL2의 증가와 비례하는 것으로 알려져 있다(Taskinen, M. R.; Kahri, J.; Koivisto, V.; Shepherd, J.; Dackard, C. J. Metabolism of HDL apolipoprotein AⅠ and AⅡ in type Ⅰ(insulindependent) diabetes mellitus. Diabetologia. 1992, 35: 347-356. 참조). 한편 apolipoprotein CⅢ는 VLDL, IDL, HDL의 구성 단백으로서 LPL을 억제하여 혈중 콜레스테롤 증가하는 기능이 있는 것으로 알려져 있다(Gotto, A. M.; Pownall, H. J.; Havel, R. A. Introduction to the plasma lipoproteins. Methods Enzymol. 1986, 128, 3-40. 참조).Among them, apolipoprotein AⅠ is not only an important lipoprotein constituting chylomicron and HDL cholesterol, but also activates LCAT, and apolipoprotein AII is an important component protein of HDL cholesterol (58). In particular, the increase in apolipoprotein AI and apolipoprotein AII is known to be proportional to the increase of HDL2, which plays a role in anti-arteriosclerosis (Taskinen, MR; Kahri, J .; Koivisto, V .; Shepherd, J .; Dackard, CJ Metabolism of HDL apolipoprotein AI and AII in type I (insulindependent) diabetes mellitus.Diabetologia . 1992 , 35: 347-356. The apolipoprotein CⅢ is VLDL, IDL, is to suppress LPL as a constituent protein of HDL known to have the ability to increase blood cholesterol (Gotto, AM;. Pownall, HJ;. Havel, RA Introduction to the plasma lipoproteins Methods Enzymol 1986, 128, 3-40.
FD와 녹두를 2.5, 5, 10% 되도록 첨가한 FD-Mung bean군의 apolipoprotein의 분비량 검색은 대조군을 100으로 보았을 때 apolipoproteinAⅠ, apolipoprotein AⅡ, apolipoprotein CⅢ의 분비량이 각각 도 6 내지 8과 같이 나타났다.Searching for apolipoprotein secretion of the FD-Mung bean group to which FD and mung beans were added at 2.5, 5, and 10%, the secretion of apolipoproteinA I, apolipoprotein AII, and apolipoprotein CIII was 100, respectively, as shown in FIGS.
먼저, apolipoprotein AⅠ의 경우 FD보다 녹두를 첨가하였을 때, 분비량이 증가하였고, 특히 2.5%로 녹두를 첨가한 FD-Mung bean군이 유의적으로 가장 높은 분비량을 나타냈다. Apolipoprotein AⅡ 역시 녹두를 2.5%로 첨가한 FD-Mung bean군에서 분비량이 가장 높은 것으로 나타났다. 반면 apolipoprotein CⅢ의 분비량은 녹두를 2.5% 첨가한 FD-Mung bean군에서 가장 낮은 분비량을 나타냈다. 따라서 녹두를 2.5% 첨가한 FD-Mung bean군은 콜레스테롤의 역수송 운반체로서 항동맥경화 인자로 작용하는 HDL을 주로 구성하는 apolipoprotein AⅠ, AⅡ를 증가시키고 VLDL, IDL, HDL을 구성하는 apolipoprotein CⅢ의 분비를 저해함을 확인할 수 있었다.First, in the case of apolipoprotein AⅠ, the amount of secretion was increased when Mung was added than FD. Especially, FD-Mung bean group with 2.5% showed the highest secretion. Apolipoprotein AⅡ also showed the highest secretion rate in the FD-Mung bean group containing 2.5% mung bean. On the other hand, the secretion of apolipoprotein CIII was the lowest in the FD-Mung bean group containing 2.5% of green beans. Therefore, the FD-Mung bean group containing 2.5% of mung beans increased the apolipoproteins A and A II, which constitute HDL, which acts as an anti-arteriosclerosis factor, and secreted apolipoprotein CIII, which constitutes VLDL, IDL, and HDL. It was confirmed that inhibition.
이와 같이 in vitro 상에서 콜레스테롤 조절능을 검색한 결과, FD 자체가 콜레스테롤 조절능이 있었으며, 여기에 녹두를 2.5% 첨가하여 발효시키면 콜레스테롤 조절능이 더 우수해지는 것을 확인하였다. 하지만 녹두를 5, 10% 되도록 더 첨가하게 되면 오히려 콜레스테롤 조절능이 감소되는 것으로 확인되었다. 따라서 FD와 효과가 가장 우수했던 녹두를 2.5%로 첨가한 FD-Mung bean군의 이화학적 특성 및 in vivo 상에서의 지질대사 및 콜레스테롤 개선능을 검색하였다.As a result of searching for cholesterol control ability in vitro , FD itself had cholesterol control ability, and when fermented with 2.5% of green beans, it was confirmed that cholesterol control ability was better. However, when the amount of mung beans added to 5, 10% more cholesterol control ability was found to decrease. Therefore, the physicochemical characteristics of FD-Mung bean group added 2.5% of green beans, which had the best effect with FD, were analyzed for lipid metabolism and cholesterol improvement in vivo .
2. 발효물의 이화학적 특성분석2. Physicochemical Characterization of Fermented Products
1) FD 및 FDM의 이화학적 특성검색1) Search for Physicochemical Properties of FD and FDM
DSG를 발효시킨 FD와 in virto 상에서 콜레스테롤 저해 효과가 가장 우수했던 2.5% 녹두를 첨가한 DSG 발효물 (FDM)의 pH와 tyrosine 함량 및 가수분해효소 활성을 측정한 결과를 다음 표 4에 나타내었다. The results of measuring the pH, tyrosine content and hydrolase activity of DSG fermentation (FDM) added 2.5% mung bean, which had the highest cholesterol inhibitory effect on FD and in virto fermented DSG, are shown in Table 4 below.
pH는 DSG가 6.48로 나타났고, 발효한 FD와 FDM은 각각 6.91과 6.96으로 상승하였다. The pH of the DSG was 6.48 and the fermented FD and FDM rose to 6.91 and 6.96, respectively.
DSG 발효물의 peptide 생성정도를 측정하기 위하여 tyrosine 함량을 측정한 결과 DSG가 약 95.6 mg%로 나타났고 발효시킨 FD와 FDM은 각각 1893.42, 1973.96 mg%로 약 20배 이상 증가하였고 특히 녹두를 첨가한 FDM이 FD보다 함량이 더 증가한 것으로 나타났다. In order to measure the degree of peptide production of DSG fermentation, the results of measuring tyrosine showed that DSG was about 95.6 mg%, and the fermented FD and FDM were increased by about 20 times to 1893.42 and 1973.96 mg%, respectively. It was found that the content increased more than this FD.
Protease는 대두의 단백질을 분해하여 대두 발효물의 맛을 형성하는데 가장 중요한 역할을 하는 것으로 알려져 있다(Lee, K. H.; Lee, H. J.; Chung, M. K. Studies on Chungkookjang. on the changes of soybean protein in manufacturing Chungkookjang. J. Korean Agric. Chem. 1971, 14, 191-200. 참조). 발효물의 가수분해효소 활성을 검색한 결과 protease 활성은 FD와 FDM에서 각각 482.46, 507.83 unit/g으로 FDM에서 높게 나타났으며 α-amylase 활성 역시 FD와 FDM이 각각 24.38, 38.29 unit/g으로 FDM에서 높게 나타났다. 이들 결과로 보아 적정량의 녹두 첨가가 균주의 생육을 촉진시켜 가수분해효소의 활성을 증가시킨 것으로 생각된다. Protease is known to play a most important role in forming taste fermented soybean water by digesting the protein of soybean (Lee, KH; Lee, HJ ;.. Chung, MK Studies on Chungkookjang on the changes of soybean protein in manufacturing Chungkookjang J Korean Agric.Chem. 1971, 14, 191-200. The protease activity was higher in FDM and 482.46 and 507.83 unit / g in FD and FDM, respectively, and the α-amylase activity in both FD and FDM was 24.38 and 38.29 unit / g, respectively. High. These results suggest that the addition of an appropriate amount of mung beans promoted the growth of the strain and increased the activity of the hydrolase.
2) FD 및 FDM의 점조도 및 점질물 함량 검색2) Searching consistency and viscosity content of FD and FDM
Bacillus 균주의 발효대사산물인 점질물은 glutamic acid가 약 5,000개가 중합된 γ-polyglutamic acid(PGA)와 과당의 중합체인 fructan 형태의 레반으로 구성되어 있다(Lee, Y. L.,; Kim, S. H.; Choung, N. H.; Tim, M. H. A study on the production of viscous substance during the Chungkookjang fermentation. J. Korean Agirc. Chem. Soc. 1992, 5, 202-209. 참조). 이러한 점질물은 제품의 품질특성에 중요한 영향을 미치며, 특히 여러 생리활성기능을 가지고 있어 식품, 의약품 뿐만 아니라 화장품으로도 각광받고 있는 기능성 소재이다(Choi, H. J.; Kunioka, M. Preparation conditions and swelling equilibria of hydrogel prepared by (γ-irradiation from microbiol poly(γ-glutamic acid)). radiat. Phys. Chem. 1995, 46, 175-179. 참조). Viscous , a fermentative metabolite of Bacillus strains, consists of γ-polyglutamic acid (PGA) polymerized with approximately 5,000 glutamic acids and a fructan-type levan, a polymer of fructose (Lee, YL, Kim, SH; Choung, NH). Tim, MH A study on the production of viscous substance during the Chungkookjang fermentation. J. Korean Agirc. Chem. Soc . 1992, 5, 202-209. These viscous substances have an important influence on the quality characteristics of products, and in particular, they have various physiologically active functions and are functional materials that are attracting attention as foods and medicines as well as cosmetics (Choi, HJ; Kunioka, M. Preparation conditions and swelling equilibria of hydrogel prepared by (γ-irradiation from microbiol poly (γ-glutamic acid)). radiat.Phys.Chem. 1995 , 46, 175-179.
FD 및 FDM을 10배 물로 희석하여 여과한 추출액의 점조도 및 점질물 함량을 다음 표 4에 나타내었다. The consistency and viscosity of the extracts filtered by diluting FD and FDM with 10-fold water are shown in Table 4 below.
DSG에서는 점조도나 점질물 함량이 아주 낮거나 측정되지 않았지만 FD에서는 0.966 Pa·sn 이하의 점조도 값을 나타내었고 점질물 함량은 DSG에 비해 20배 이상의 높은 함량을 나타내었다. 특히 녹두를 첨가하여 발효시킨 FDM은 점조도 값이 1.679 Pa·sn 로 FD보다 높게 측정되었고, 점질물 함량 역시 FD보다 약 3% 정도 더 높게 측정되었다. 따라서 DSG에 녹두를 첨가하여 발효시키게 되면 점질물 생산이 증대되는 것을 확인할 수 있었다. In DSG, the consistency or viscosity content was very low or not measured. In FD, the consistency value was less than 0.966 Pa · s n and the viscosity content was 20 times higher than that of DSG. In particular, FDM fermented with mung beans had a consistency value of 1.679 Pa · s n, which was higher than that of FD, and the viscous content was about 3% higher than that of FD. Therefore, when fermented by adding mung beans to DSG, it was confirmed that the production of viscous substances is increased.
(Pa·sn )Consistency index
(Pas n )
content (%)Viscous substance
content (%)
1)D: 탈지대두박 FD: 탈지대두박 발효물 FDM: 녹두 첨가한 탈지대두박 발효물 1) D: Defatted soybean meal FD: Defatted soybean meal FDM: Defatted soybean meal fermented with green beans
ND: Not DetectedND: Not Detected
3. FD 및 FDM의 콜레스테롤 및 지질대사 개선효과3. Effects of FD and FDM on Cholesterol and Lipid Metabolism
1) 체중증가량 및 식이섭취량에 미치는 영향1) Effect on weight gain and dietary intake
FD 및 FDM의 지질대사 및 콜레스테롤 개선 효과를 확인하고자, SD계열 랫트에 콜레스테롤 1%, lard 10%, sodium cholate 0.25%를 첨가한 식이로 4주간 사육한 동물의 체중변화를 다음 표 5에 나타내었다. To confirm the lipid metabolism and cholesterol-improving effects of FD and FDM, the weight change of animals reared for 4 weeks with diets containing 1% cholesterol, lard 10% and sodium cholate 0.25% in SD rats is shown in Table 5 below. .
4주 후 각 군별의 체중증가량은 대조군보다 HF군에서 유의적으로 증가하였다. 고지방식이에 FD 및 FDM을 첨가한 그룹에서는 HF군보다 체중이 감소하였지만 유의적인 감소는 없었다. 또한 사료효율 역시 각 군별 유의적인 차이가 없었다. After 4 weeks, weight gain in each group was significantly higher in HF group than in control group. In the high fat diet, FD and FDM added body weights were lower than the HF group, but there was no significant decrease. Feed efficiency was also not significantly different between groups.
(g/4 weeks)Weight loss
(g / 4 weeks)
The values are mean ± S.D.(n=6).The values are mean ± S.D. (n = 6).
Values with a common superscript letter within the same column are not significantly different(ρ<0.05).Values with a common superscript letter within the same column are not significantly different (ρ <0.05).
1)군은 상기 표 2에 나타낸 것과 같다. 1) Groups are as shown in Table 2 above.
2)FER: food efficiency ratio=body weight gain/food intake 2) FER: food efficiency ratio = body weight gain / food intake
ns: not significant ns: not significant
2) 장기무게에 미치는 영향2) Effect on long-term weight
단위 체중 당 장기무게는 다음 표 6에 나타내었다. The organ weight per unit weight is shown in Table 6 below.
체중 100 g 당 무게로 환산한 장기의 중량을 비교한 실험에서 간장 무게는 대조군에 비해 HF군에서 유의적으로 증가되었다. 이는 콜레스테롤 식이에 의한 영향으로 보이며, 간장의 중성지질 농도와 총 콜레스테롤 농도 때문에 간장 중량 역시 증가한 것으로 보인다. 이에 반해 HF-FD군 및 HF-FDM군에서 HF군에 비해 무게가 감소되었고 특히 HF-FDM군은 HF군에 비해 유의적으로 간장의 무게가 감소하는 것으로 나타났다. 이는 FD와 FDM을 처리함으로써 간장의 지방 침착을 감소시켜 무게가 감소되고, 녹두를 첨가한 발효물인 FDM이 간장 내의 지방 침착을 더 감소시키는 것으로 보인다.In the experiment comparing the weight of organs in terms of weight per 100 g body weight, the liver weight was significantly increased in the HF group compared to the control group. This may be due to the cholesterol diet, and liver weight also appears to be increased due to the concentration of triglycerides and total cholesterol in the liver. In contrast, the HF-FD and HF-FDM groups showed reduced weight compared to the HF group, and in particular, the HF-FDM group showed significantly lower liver weight than the HF group. This reduces the fat deposition of soy by treating FD and FDM, resulting in reduced weight, and it appears that FDM, a fermented product with green beans, further reduces fat deposition in soy.
이 등(Rhee, S. J.; Park, H. K. Changes of lipid concentration and histochemical observation in liver of rats fed high fat diet. J. Nutr. 1984, 17, 113-125. 참조)은 식이로 섭취한 과량의 콜레스테롤이 체외로 정상적으로 배출되지 못하고 간장 내에 축적되면 간장이 비대해 진다고 하였으며, Thrley 등(Thrley, E.; Armstrong, N. C.; Wallace, J. M.; Gilore, W. S.; Mckelvey-matin, J. V.; Allen, T. M.; Strain, J. J. Effect of cholesterol feeding on DNA damage in male and female syrian hamsters. Ann. Nutr. Merab. 1990, 43, 48-51. 참조)도 콜레스테롤을 장기간 급여할 때 간 비대증을 유발시켜, 지방의 과잉 섭취 및 지질 대사 이상을 초래하여 간장조직에 지방이 침착된다고 보고하였다. 본 연구에서도 대조군에 비해 HF군에서 간장 조직에 지방이 침착된 것을 확인하였다.Lee et al. (Rhee, SJ; Park, HK Changes of lipid concentration and histochemical observation in liver of rats fed high fat diet.See J. Nutr . 1984, 17, 113-125.) If it is not normally discharged, it accumulates in the liver, and it is said that the liver is enlarged. Thrley et al. (Thrley, E .; Armstrong, NC; Wallace, JM; Gilore, WS; Mckelvey-matin, JV; Allen, TM; Strain, JJ Effect) of cholesterol feeding on DNA damage in male and female syrian hamsters.Ann. Nutr.Merab. 1990 , 43, 48-51.) also cause hepatomegaly in long-term feeding of cholesterol, resulting in excess fat intake and lipid metabolism It has been reported that fat deposits in hepatic tissue. This study also confirmed that fat was deposited in the liver tissues in the HF group compared to the control group.
그러나 간장을 제외한 나머지 비장, 신장, 부고환 지방 및 복부지방의 최종 무게는 모든 군에서 유의한 차이가 보이지 않았으나 HF군에서 가장 높았고, 복부지방과 복부비만의 척도로 여겨지는 부고환지방의 체중에 대한 비율은 유의하지 않았지만 FD와 FDM을 첨가한 군에서 무게가 감소되는 것으로 나타났다.However, the final weights of the spleen, kidney, epididymal fat and abdominal fat, except for liver, were not significantly different in all groups, but were highest in the HF group and the percentage of epididymal fat, which is considered as a measure of abdominal fat and abdominal obesity. Was not significant, but the weight was decreased in the FD and FDM groups.
The values are mean ± S.D.(n=6).The values are mean ± S.D. (n = 6).
Values with a common superscript letter within the same column are not significantly different(ρ<0.05).Values with a common superscript letter within the same column are not significantly different (ρ <0.05).
ns: not significantns: not significant
3) 혈장의 중성지질 및 콜레스테롤 농도3) plasma triglyceride and cholesterol concentration
고지방식이와 FD 및 FDM을 섭취시킨 흰쥐를 사육하는 동안 2주차와 4주차의 혈장내의 중성지질 및 콜레스테롤 함량 변동을 쇄골 대정맥에서 채혈 후 혈장을 분리하여 측정한 결과는 도 9 및 10에 나타내었다. Changes in plasma triglyceride and cholesterol contents in plasma at
혈장 중의 중성지질은 콜레스테롤의 합성을 촉진시켜 혈중 콜레스테롤을 증가시키는 것(Lee, H. J. Effects of dietary casein. soy protein and mixed protein on body lipid components of rats. Master thesis, Sung-shin women's University, Seoul, 1986. 참조)으로 알려져 있다. 혈장 중 중성지질의 함량은 대조군에 비해 HF군에서 유의적으로 증가되었으나 고지방식이에 FD 및 FDM을 첨가한 군에서는 중성지질 함량이 유의적으로 감소되었고 특히 녹두를 첨가하여 발효한 FDM 첨가군이 가장 낮은 중성지질 함량을 보였다(도 9의 A)). (Lee, HJ Effects of dietary casein. Soy protein and mixed protein on body lipid components of rats.Master thesis, Sung-shin women's University, Seoul, 1986 Is known as. The plasma triglyceride content was significantly increased in the HF group compared to the control group, but the neutral lipid content was significantly decreased in the FD and FDM groups, especially in the FDM group fermented with green beans. It showed a low triglyceride content (FIG. 9A).
혈장 중 총 콜레스테롤 농도는 도 9의 B)와 같이 2주차에서는 모든 HF군에서 대조군에서보다 유의적으로 콜레스테롤 함량이 증가 되었다가 4주차에서는 FD와 FDM 첨가군에서는 HF군보다 유의적으로 콜레스테롤 함량이 감소되었다. Plasma total cholesterol concentration was significantly increased in the HW group as compared to the control group in the 2nd week as shown in B) of FIG. 9, but in the 4th week FD and FDM added cholesterol content was significantly higher than the HF group Reduced.
LDL 콜레스테롤 농도가 증가되면 심혈관계 질환의 매우 중요한 위험인자로 알려져 있는 oxLDL의 함량을 증가시키게 된다(Parthasarathyl, S.; Santanam, N.; Auge, N. Oxidized low-density lipoprotein, a two-faced janus in coronary artery disease. Biochem. Pharmacol. 1998, 56, 279-284. 참조). 혈장 중 LDL 콜레스테롤 함량도 모든 HF군에서 대조군에 비해 유의적으로 증가되었으나 고지방식이에 FD와 FDM 첨가군은 HF군에 비해 LDL 콜레스테롤의 함량이 유의적으로 감소되었으며 특히 FDM을 첨가한 군은 고지방 식이군 중 가장 낮은 LDL-콜레스테롤 함량을 보였다(도 10의 A)).Increasing LDL cholesterol increases oxLDL content, a very important risk factor for cardiovascular disease (Parthasarathyl, S .; Santanam, N .; Auge, N. Oxidized low-density lipoprotein, a two-faced janus). in coronary artery disease. Biochem. Pharmacol . 1998, page 56, 279-284.). Plasma LDL cholesterol content was significantly increased in all HF groups compared to the control group, but the FD and FDM groups in the high-fat diet significantly reduced the LDL cholesterol content in comparison with the HF group. Lowest LDL-cholesterol content in the diet group (Fig. 10 A)).
반면 혈장 중 HDL 콜레스테롤 함량은 대조군에 비해 HF군에서 유의적으로 증가하였고 고지방식이와 FD 첨가군의 경우 HDL 콜레스테롤이 증가하였고 특히 FDM 첨가군은 유의적으로 HDL 콜레스테롤이 증가되었다(도 10의B)). HDL 콜레스테롤은 말초조직이나 혈액 중에 축적된 콜레스테롤을 콜레스테롤 에스테르로 만들어 간으로 수송하여 혈액 중 콜레스테롤 함량을 저하시켜 동맥경화증의 개선 및 예방에 효과가 있다고 알려져 있으며, LDL 콜레스테롤 함량과 역상관 관계를 유지한다(Lee, H. J. Effects of dietary casein. soy protein and mixed protein on body lipid components of rats. Master thesis, Sung-shin women's University, Seoul, 1986.; Fernandez, M. L.; Mcnamara, D. J. Regulation of cholesterol and lipoprotein metabolism in guinea pogs mediated by dietary fat quality and quantity. J. Nutr. 1991, 121: 934-943. 참조). 따라서 FD 및 FDM은 고지방식이에 의해 증가된 LDL 콜레스테롤 함량은 감소시키고 HDL 콜레스테롤 함량은 증가시켜 고콜레스테롤증 예방에 관여할 것으로 기대된다. In contrast, the HDL cholesterol content in plasma was significantly increased in the HF group compared to the control group, HDL cholesterol was increased in the high fat diet and the FD group, and HDL cholesterol was significantly increased in the FDM group (Fig. 10B). )). HDL cholesterol is known to be effective in improving and preventing arteriosclerosis by lowering cholesterol in blood by transporting cholesterol accumulated in peripheral tissues or blood to cholesterol esters, and maintaining a negative correlation with LDL cholesterol content. (Lee, HJ Effects of dietary casein.soy protein and mixed protein on body lipid components of rats.Master thesis, Sung-shin women's University, Seoul, 1986 .; Fernandez, ML; Mcnamara, DJ Regulation of cholesterol and lipoprotein metabolism in guinea pogs mediated by dietary fat quality and quantity.J. Nutr. 1991, 121: 934-943.). Therefore, FD and FDM are expected to be involved in the prevention of hypercholesterolemia by decreasing the LDL cholesterol content increased by the high fat diet and increasing the HDL cholesterol content.
4) 간 조직의 HMG-CoA reductase 활성4) HMG-CoA reductase activity in liver tissue
간 내 HMG-CoA reductase는 콜레스테롤 생합성 과정에서 중요한 조절 효소로서, 이 효소의 저해는 세포 내에서 콜레스테롤 합성을 억제한다고 알려져 있다. HMG-CoA reductase 저해제는 혈중 콜레스테롤 특히 LDL 콜레스테롤을 가장 효과적으로 낮출 수 있는 hypocholesterolemic 약제로 널리 사용되고 있다(Fujioka, T.; Nara, F.; Tsujita, Y.; Fukushige, J.; Fukami, M.; Kuroda, M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. BBA. 1995, 1254, 7-12. 참조). 일반적으로 사틴계열의 약물이 혈장 총 콜레스테롤 및 LDL 콜레스테롤을 낮추는 기전은 간에서 HMG-CoA reductase의 활성을 억제하여 콜레스테롤 생합성을 억제함으로써 간의 LDL receptor의 발현을 촉진시켜 혈중의 지질농도를 저하시킨다고 알려져 있다(Igel, M.; Sudhop, T.; vonBergmann, K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 2001, 57, 357-364.; Paoletti, R.; Corsini, A.; Bellosta, S. Pharmacologicl interactions of statins. Atherosclerosis Supplements. 2002, 3, 35-40. 참조). Hepatic HMG-CoA reductase is an important regulator of cholesterol biosynthesis, and its inhibition is known to inhibit cholesterol synthesis in cells. HMG-CoA reductase inhibitors are widely used as hypocholesterolemic agents that can most effectively lower blood cholesterol, especially LDL cholesterol (Fujioka, T .; Nara, F .; Tsujita, Y .; Fukushige, J .; Fukami, M .; Kuroda , M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats.BBA . 1995 , 1254, 7-12.). In general, the mechanism by which satin-based drugs lower plasma total cholesterol and LDL cholesterol is known to inhibit the activity of HMG-CoA reductase in the liver, thereby inhibiting cholesterol biosynthesis, thereby promoting the expression of LDL receptor in the liver, thereby lowering blood lipid concentration. (Igel, M .; Sudhop, T .; vonBergmann, K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 2001, 57, 357-364 ; Paoletti, R .; Corsini, A .; Bellosta, S. Pharmacologicl interactions of statins.Atherosclerosis Supplements. 2002, 3, 35-40.).
HMG-CoA reductase의 활성변동은 도 11에 나타내었다. HMG-CoA reductase 활성은 대조군에 비해 HF군에서 크게 증가되었다가, HF-FD, HF-FDM군에서 유의성 있게 감소되었다. 고지방식이군의 HMG-CoA reductase 활성의 증가는 고지방 및 고콜레스테롤 식이에 의한 결과로 생각되고, FD 및 FDM 첨가에 의해 혈중 콜레스테롤 함량이 감소하는 것은 FD와 FDM 성분이 내인성 콜레스테롤 합성의 중요한 효소인 HMG-CoA reductase의 활성을 저해하여 나타난 결과로 생각된다.The activity variation of HMG-CoA reductase is shown in FIG. 11. HMG-CoA reductase activity was significantly increased in the HF group compared to the control group, but significantly decreased in the HF-FD and HF-FDM groups. Increasing HMG-CoA reductase activity in high fat diet group is thought to be a result of high fat and high cholesterol diet, and the decrease of blood cholesterol content by FD and FDM addition is important for HMG, which is an important enzyme for endogenous cholesterol synthesis. This may be due to the inhibition of CoA reductase activity.
5) 간 조직의 지질 함량에 미치는 영향5) Effect on the lipid content of liver tissue
고지방 또는 콜레스테롤의 섭취에 의해 간 조직에서 지질대사 이상이 초래되어 지질의 침착에 의해 간의 무게가 증가하고 간에서의 지질과 콜레스테롤 함량이 증가한다고 알려져 있다. It is known that the intake of high fat or cholesterol causes abnormal lipid metabolism in the liver tissue, which increases the weight of the liver and increases the lipid and cholesterol content in the liver by the deposition of lipids.
간의 지질함량 변동은 도 12에 나타낸 것과 같다. 콜레스테롤 함량은 대조군에 비해 HF군에서 유의적으로 증가되었으나, HF-FD군은 HF군에 비해 콜레스테롤 농도가 줄었지만 유의성이 없는 데에 반해 HF-FDM군은 유의적으로 콜레스테롤 함량이 감소되었다. 중성지질 함량의 경우에도 콜레스테롤 함량변동과 유사하게 HF군에서 함량이 증가되었다가 HF-FDM군에서 유의성 있는 감소를 보였다. Lipid content variation of the liver is as shown in FIG. Cholesterol content was significantly increased in the HF group compared to the control group, while HF-FD group showed a lower cholesterol level than the HF group, but the HF-FDM group significantly decreased the cholesterol content. In the case of triglyceride content, the content was increased in HF group and similarly decreased in HF-FDM group.
6) 분변의 지질 농도에 미치는 영향6) Effect on Fecal Lipid Concentration
분변으로의 총 콜레스테롤, 중성지질의 배설량은 도 13Fig. 13에 나타내었다. 분변 중의 콜레스테롤 함량은 대조군에 비해 HF군에서는 유의적인 차이가 없었지만 HF-FD군과 HF-FDM군에서는 유의적으로 콜레스테롤 배설량이 증가되었고 특히 HF-FDM군에서 콜레스테롤 농도가 가장 증가되었다. 중성지질 농도는 대조군에 비해 HF군에서 배설량이 증가되었으나 HF-FD군과 HF-FDM군에서는 중성지질 배설량이 유의적으로 증가되었고 콜레스테롤 배설량과 마찬가지로 HF-FDM군에서 중성지질 배설량이 유의적으로 가장 높았다. 즉 고지방식이에 FD와 FDM을 첨가함으로서 HF군에 비해 분변으로의 총콜레스테롤 및 중성지질의 배설량이 증가되었다. Excretion of total cholesterol and triglycerides into feces is shown in Fig. It is shown in 13. The fecal cholesterol content was not significantly different in the HF group compared to the control group, but cholesterol excretion was significantly increased in the HF-FD and HF-FDM groups, and cholesterol concentration was the highest in the HF-FDM group. Neutral lipid concentration was increased in HF group compared with control group, but neutral lipid excretion was significantly increased in HF-FD group and HF-FDM group. Neutral lipid excretion was significantly higher in HF-FDM group. High. In other words, the addition of FD and FDM to the high fat diet increased the amount of total cholesterol and neutral lipid excretion in feces compared to the HF group.
따라서 FD와 FDM은 체내 콜레스테롤 및 중성지질의 함량을 조절하여 체내 지질대사 개선에 관여할 수 있는 소재로 생각된다. Therefore, FD and FDM are thought to be a material that can be involved in improving lipid metabolism in the body by regulating the content of cholesterol and neutral lipid in the body.
7) 간과 복부지방 및 부고환지방의 병리학적 변화 7) Pathological changes of liver, abdominal fat and epididymal fat
각 군의 간 조직의 형태학적 분석결과는 도 14와 같다. 대조군에 비해 고지방 섭취군인 HF군에서 지방구가 가장 많이 축적되었으며 지방구의 크기도 가장 큰 것으로 관찰되었다. 이에 반해 HF-FD군과 HF-FDM군에서는 HF군보다 지방구의 크기가 감소되는 것을 확인하였고, 특히 HF-FDM군이 HF-FD군보다 효과가 더 우수한 것으로 관찰되었다.Morphological analysis of liver tissues of each group is shown in FIG. 14. Compared with the control group, the HF group, which had high fat intake, had the most accumulation of fat globules and the largest size of fat globules. In contrast, the HF-FD group and the HF-FDM group were found to reduce the size of fat globules than the HF group. In particular, the HF-FDM group was observed to be more effective than the HF-FD group.
각 군의 복부 지방세포와 부고환 지방세포의 형태학적 분석결과는 각각 도 15 및 16에 나타내었다. 먼저, 복부 지방세포의 크기가 대조군에 비해 HF군에서 커졌다가 HF-FD군과 HF-FDM군에서 지방세포의 크기가 다시 감소되었으며, 부고환 지방세포의 변화 역시 복부 지방세포와 마찬가지로 HF-FD군과 HF-FDM군이 HF군의 지방세포 크기보다 감소되는 것으로 나타났다.Morphological analysis of abdominal fat cells and epididymal fat cells of each group is shown in FIGS. 15 and 16, respectively. First, the size of abdominal adipocytes was larger in HF group than in control group, but in the HF-FD group and HF-FDM group, the size of adipocytes was reduced again. And HF-FDM groups were reduced than adipocyte size of HF group.
결과적으로 고지방 식이의 섭취로 인해 간세포나 지방세포에 지질의 침착 정도가FD와 FDM 첨가시에 경감되는 효과를 보이는 것은, 발효되면서 생성되는 점질물성분과 peptide등의 성분에 의한 것으로 생각된다.As a result, the fact that the deposition of lipids in hepatocytes or adipocytes due to the intake of high-fat diets is reduced by the addition of FD and FDM is thought to be due to the components of viscous substances and peptides produced during fermentation.
도 1은 탈지대두박 발효물의 제조공정 및 녹두 첨가 탈지대두박 발효물의 제조공정을 개략적으로 도시한 것. Figure 1 schematically shows the manufacturing process of the skim soybean meal fermentation and the manufacturing process of the skim soybean meal fermented with green beans.
도 2는 식용 식물의 80% 메탄올 추출물의 HMG-CoA 리덕타아제 저해 활성을 검색한 결과를 나타낸 막대 그래프로서, Figure 2 is a bar graph showing the results of searching for HMG-CoA reductase inhibitory activity of 80% methanol extract of edible plants,
I는 황금, Ⅱ는 능이버섯, Ⅲ은 커리플라워, Ⅳ는 당귀, Ⅴ는 상황버섯, Ⅵ은 감초, Ⅶ은 치커리, Ⅷ은 몰로키아, Ⅸ은 녹두를 나타냄.I is golden, II is Twill mushroom, III is curry flower, IV is Angelica, V is situational mushroom, VI is licorice, young chicory, young Molokia, young green bean.
도 3은 FD 및 DSG에 대해 녹두를 각각 2.5%, 5% 및 10%로 첨가한 군(FD-Mung bean.)에 대한 콜레스테롤 흡착정도 평가 결과를 도시한 막대 그래프. FIG. 3 is a bar graph showing the results of evaluation of cholesterol adsorption degree for the group (FD-Mung bean.) In which green beans were added at 2.5%, 5% and 10% for FD and DSG, respectively.
도 4는 FD 및 DSG에 대해 녹두를 각각 2.5%, 5% 및 10%로 첨가한 군(FD-Mung bean.)에 대한 HMG-CoA 리덕타아제 저해활성을 평가한 결과를 도시한 막대 그래프.Figure 4 is a bar graph showing the results of evaluating the HMG-CoA reductase inhibitory activity against the group (FD-Mung bean.) Added Mung beans 2.5%, 5% and 10% for FD and DSG, respectively.
도 5는 각 시료에 의한 세포 내 콜레스테롤 함량 측정의 결과를 나타낸 막대 그래프.F5 is a bar graph showing the results of measuring the intracellular cholesterol content by each sample.
도 6 내지 도 8은 FD 및 DSG에 대해 녹두를 각각 2.5%, 5% 및 10%로 첨가한 군(FD-Mung bean.)에 의한 HepG2 cell로부터 apolipoprotein AⅠ 분비량 검색 결과(도 6), apolipoprotein A Ⅱ 분비량 검색 결과(도 7) 및 apolipoprotein CⅢ 분비량 검색 결과(도 8).6 to 8 shows the results of apolipoprotein A I secretion from HepG2 cells by the group (FD-Mung bean.) In which Mung beans were added 2.5%, 5% and 10% for FD and DSG, respectively (FIG. 6), apolipoprotein A II secretion search results (Fig. 7) and apolipoprotein CIII secretion search results (Fig. 8).
도 9 및 도 10은 고지방 식이와 FD 및 DSG에 대해 녹두를 각각 2.5%, 5% 및 10%로 첨가한 군(FD-Mung bean.)을 섭취시킨 흰쥐를 사육하는 동안 2주차와 4주차의 현장내의 중성지질 및 콜레스테로 함량 변동을 쇄골 대정맥에서 채현한 후 혈장 을 분리하여 측정한 결과를 도시한 것으로, 도 9는 트리글리세라이드(A) 및 총 콜레스테롤(B) 함량에 대한 것이고, 도 10은 HDL 콜레스테롤(A) 및 LDL 콜레스테롤(B) 함량을 도시한 것.9 and 10 show the high-fat diet and
도 11은 각각의 식이방법에 따라 4주간 식이한 후의 간내의 HMG-CoA 리덕타아제 활성변동을 도시한 것.Figure 11 shows the changes in HMG-CoA reductase activity in the liver after four weeks of dietary method according to each diet.
도 12는 각각의 식이방법에 따라 4주간 식이한 후의 간의 지질함량 변동을 도시한 것.Figure 12 shows the lipid content of the liver after diet for four weeks according to each diet method.
도 13은 각각의 식이방법에 따라 4주간 식이한 후의 분별으로의 총 콜레스테롤, 중성지질의 배설량을 도시한 것.Figure 13 shows the amount of excretion of total cholesterol, triglycerides by fractionation after dieting for 4 weeks according to each diet method.
도 14는 각각의 식이방법에 따라 4주간 식이한 후의 간 조직의 형태학적 분석 결과( H&E staining. X 400).Figure 14 shows the results of morphological analysis of liver tissues after dieting for 4 weeks according to each diet (H & E staining. X 400).
도 15는 각각의 식이방법에 따라 4주간 식이한 후의 복부 지방세포의 형태학적 분석 결과( H&E staining. X 400).Figure 15 shows the results of morphological analysis of abdominal fat cells after 4 weeks of diet according to each diet (H & E staining. X 400).
도 16은 각각의 식이방법에 따라 4주간 식이한 후의 부고환 지방세포의 형태학적 분석 결과( H&E staining. X 400).Figure 16 shows the results of morphological analysis of epididymal adipocytes after 4 weeks of dietary treatment (H & E staining. X 400).
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090010566A KR101082421B1 (en) | 2009-02-10 | 2009-02-10 | Food for improving cholesterol and lipid metabolism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090010566A KR101082421B1 (en) | 2009-02-10 | 2009-02-10 | Food for improving cholesterol and lipid metabolism |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100091393A true KR20100091393A (en) | 2010-08-19 |
KR101082421B1 KR101082421B1 (en) | 2011-11-11 |
Family
ID=42756586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090010566A KR101082421B1 (en) | 2009-02-10 | 2009-02-10 | Food for improving cholesterol and lipid metabolism |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101082421B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012078004A3 (en) * | 2010-12-09 | 2012-09-27 | (주)아모레퍼시픽 | Composition comprising fermented tea extracts for reducing lipid level |
-
2009
- 2009-02-10 KR KR1020090010566A patent/KR101082421B1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012078004A3 (en) * | 2010-12-09 | 2012-09-27 | (주)아모레퍼시픽 | Composition comprising fermented tea extracts for reducing lipid level |
CN103327995A (en) * | 2010-12-09 | 2013-09-25 | 株式会社爱茉莉太平洋 | Composition comprising fermented tea extracts for reducing lipid level |
CN103327995B (en) * | 2010-12-09 | 2016-05-04 | 株式会社爱茉莉太平洋 | For reducing the composition that comprises fermented tea extract of lipid level |
Also Published As
Publication number | Publication date |
---|---|
KR101082421B1 (en) | 2011-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7897182B2 (en) | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease | |
Kwak et al. | Doenjang, a fermented soybean paste, decreased visceral fat accumulation and adipocyte size in rats fed with high fat diet more effectively than nonfermented soybeans | |
KR20080003931A (en) | Treatment of insulin resistance syndrome | |
Xiang et al. | Supplementation of fermented barley extracts with lactobacillus plantarum dy-1 inhibits obesity via a UCP1-dependent mechanism | |
Tsai et al. | Effect of probiotic-fermented, genetically modified soy milk on hypercholesterolemia in hamsters | |
KR20100122333A (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of glycine max leaves as an active ingredient | |
Guo et al. | Strawberry fermentation with Cordyceps militaris has anti-adipogenesis activity | |
US20130102554A1 (en) | Composition for treatment of obesity using wheat bran extract or active ingredient isolated therefrom | |
Ahmed et al. | Hypocholesterolaemic effect of probiotic yogurt enriched with barley β-glucan in rats fed on a high-cholesterol diet | |
KR101082421B1 (en) | Food for improving cholesterol and lipid metabolism | |
KR20140114801A (en) | Composition for improving obesity and fatty liver using an extract of leaves of Sasa quelpaertensis or p-coumaric acid | |
KR101888871B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising extract from leaf of Plantago asiatica | |
KR101944295B1 (en) | Composition for improving liver function comprising fermentation product of Hovenia dulcis fruit extract | |
WO2009057954A2 (en) | Composition for improvement of fatty liver | |
KR101769592B1 (en) | Novel use of Limonium tetragonum | |
Son et al. | Comparison of anti-obesity effects of sprit vinegar and natural fermented vinegar products on the differentiation of 3T3-L1 cells and obese rats fed a high-fat diet | |
KR102057923B1 (en) | the herb extraction composite with the function of anti-hyperlipidemia | |
KR100945670B1 (en) | Composition of healthy food containing fermented soybean powder | |
KR101228554B1 (en) | The Fermentation Forming Method of Citrus Sunki And The Product thereof | |
Yoon et al. | Antiobesity effect of baek-kimchi (whitish baechu kimchi) in rats fed high fat diet | |
KR20140041632A (en) | Composition for improving obesity and fatty liver using an extract of leaves of sasa quelpaertensis or p-coumaric acid | |
KR101097838B1 (en) | A method for preparing fermented soymilk having improved good sensory property and Lipid lowering ability by Bacillus subtilis and Corni fructus, and fermented soymilk for prevention atherosclerosis obtained from this method | |
Lee et al. | Chemical Compositions before and after Lactic Acid Fermentation of Isoflavone-Enriched Soybean Leaves and Their Anti-Obesity and Gut Microbiota Distribution Effects | |
KR102141862B1 (en) | Increasing method of cordycepin of Cordyceps millitaris and bioactive compounds of strawberry and Composition for preventing or treating obesity comprising fermented extracts | |
KR20110077644A (en) | Composition for improving obesity using wheat bran |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141014 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180425 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181105 Year of fee payment: 8 |